

1 **Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus**
2 **neutralization assay allows for cross-cohort comparisons of COVID-19 sera**

3
4 Kasopecoluwa Y. Oguntuyo^{1#}, Christian S. Stevens[#], Chuan-Tien Hung¹, Satoshi
5 Ikegame¹, Joshua A. Acklin¹, Shreyas S. Kowdle¹, Jillian C. Carmichael¹, Hsin-Ping Chiu¹,
6 Kristopher D. Azarm¹, Griffin D. Haas¹, Fatima Amanat¹, Jérôme Klingler^{2,3}, Ian Baine⁴,
7 Suzanne Arinsburg⁴, Juan C. Bandres^{2,3}, Mohammed N.A. Siddiquey⁵, Robert M. Schilke⁵,
8 Matthew D. Woolard⁵, Hongbo Zhang⁵, COVIDAR Argentina Consortium⁶, Andrew J. Duty¹,
9 Thomas A. Kraus¹, Thomas M. Moran¹, Domenico Tortorella¹, Jean K. Lim¹, Andrea V.
10 Gamarnik^{1*}, Catarina E. Hioe^{1,2,3}, Susan Zolla-Pazner^{1,2}, Stanimir S. Ivanov⁵, Jeremy P.
11 Kamil⁵, Florian Krammer¹, and Benhur Lee¹

12
13 Affiliations:

- 14 1. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
15 10029
- 16 2. Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at
17 Mount Sinai, New York, NY 10029
- 18 3. James J. Peters VA Medical Center, Bronx, NY, 10468
- 19 4. Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine
20 at Mount Sinai, New York, NY, 10029
- 21 5. Department of Microbiology and Immunology, Louisiana State University Health
22 Science Center Shreveport, Shreveport, LA 71103
- 23 6. COVIDAR Argentina Consortium*, Buenos Aires, Argentina

24

25 #These authors contributed equally to this work.

26

27 *COVIDAR Argentina Consortium:

28 Ojeda DS, Gonzales Lopez Ledesma MM, Costa Navarro GS, Pallarés HM, Sanchez LN, Perez

29 P, Ostrowski M, Villordo SM, Alvarez DE, Caramelo JJ, Carradori J, Yanovsky MJ, Gamarnik

30 AV

31 i. Fundacion Instituto Leloir-CONICET, Buenos Aires, Argentina

32 ii. Universidad Nacional de San Martin, Buenos Aires, Argentina

33 iii. Laboratorio Lemos SRL, Buenos Aires, Argentina

34 iv. INBIRS-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina

35

36 Author contributions:

37 KYO, CSS and BL conceived and designed the study. KYO, CSS, CTH, SI, JAA, SSK, JCC,

38 HPC, KDA, GDH, FA, JK, IB, SA, JCB, SSI, MNAS, RMS, MDW, HZ, and COVIDAR

39 Argentina Consortium collected data. GDH, JAD, TAK, TMM, DT, JKL, AVG, CEH, SZP, SSI,

40 JPK, and FK contributed valuable reagents, data and/or tools. KYO and CSS analyzed the data

41 and wrote the original drafts of the paper. BL reviewed the draft, supported data analysis, and

42 provided invaluable direction throughout the conceptualization and execution of the project. All

43 authors had the opportunity to review the manuscript prior to submission and SI, JCC, KDA, DT,

44 and JPK provided valuable feedback during the editing process.

45

46 **Abstract**

47

48 The global COVID-19 pandemic has mobilized efforts to develop vaccines and antibody-based
49 therapeutics, including convalescent plasma therapy, that inhibit viral entry by inducing or
50 transferring neutralizing antibodies (nAbs) against the SARS-CoV-2 spike glycoprotein (CoV2-
51 S). However, rigorous efficacy testing requires extensive screening with live virus under onerous
52 BSL3 conditions which limits high throughput screening of patient and vaccine sera. Myriad
53 BSL-2 compatible surrogate virus neutralization assays (VNAs) have been developed to
54 overcome this barrier. Yet, there is marked variability between VNAs and how their results are
55 presented, making inter-group comparisons difficult. To address these limitations, we developed
56 a standardized VNA using VSVΔG-based CoV-2-S pseudotyped particles (CoV2pp) that can be
57 robustly produced at scale and generate accurate neutralizing titers within 18 hours post-
58 infection. Our standardized CoV2pp VNA showed a strong positive correlation with CoV2-S
59 ELISA and live virus neutralizations in confirmed convalescent patient sera. Three independent
60 groups subsequently validated our standardized CoV2pp VNA (n>120). Our data show that
61 absolute (abs) IC₅₀, IC₈₀, and IC₉₀ values can be legitimately compared across diverse cohorts,
62 highlight the substantial but consistent variability in neutralization potency across these cohorts,
63 and support the use of absIC₈₀ as a more meaningful metric for assessing the neutralization
64 potency of vaccine or convalescent sera. Lastly, we used our CoV2pp in a screen to identify
65 ultra-permissive 293T clones that stably express ACE2 or ACE2+TMPRSS2. When used in
66 combination with our CoV2pp, we can now produce CoV2pp sufficient for 150,000 standardized
67 VNA/week.

68

69 **Importance**

70

71 Vaccines and antibody-based therapeutics like convalescent plasma therapy are premised upon
72 inducing or transferring neutralizing antibodies that inhibit SARS-CoV-2 entry into cells. Virus
73 neutralization assays (VNAs) for measuring neutralizing antibody titers (NATs) is an essential
74 part of determining vaccine or therapeutic efficacy. However, such efficacy testing is limited by
75 the inherent dangers of working with the live virus, which requires specialized high-level
76 biocontainment facilities. We therefore developed a standardized replication-defective
77 pseudotyped particle system that mimics entry of live SARS-CoV-2. This tool allows for the safe
78 and efficient measurement of NATs, determination of other forms of entry inhibition, and
79 thorough investigation of virus entry mechanisms. Four independent labs across the globe
80 validated our standardized VNA using diverse cohorts. We argue that a standardized and scalable
81 assay is necessary for meaningful comparisons of the myriad of vaccines and antibody-based
82 therapeutics becoming available. Our data provide generalizable metrics for assessing their
83 efficacy.

84

85 **Introduction**

86
87 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an enveloped, positive-
88 sense, single-stranded RNA (+ssRNA) virus from the family *Coronaviridae*. SARS-CoV-2 is
89 related to, but not derived from SARS-CoV, which we will refer to as SARS-CoV-1 for clarity.
90 SARS-CoV-1 and SARS-CoV-2 belong to the genus *Betacoronavirus* and group together as
91 sarbecoviruses, a subgenus that also contains numerous bat “SARS-like” CoVs.¹ SARS-CoV-1
92 caused a limited epidemic of SARS from 2002-2004, infecting ~8,000 people and killing 774.^{2,3}
93 SARS-CoV-1 was ultimately contained and has not reappeared. SARS-CoV-2 is the causative
94 agent for coronavirus disease 2019 (COVID-19). The Chinese government first reported a cluster
95 of 40 cases of atypical pneumonia (now known to be COVID-19) to the WHO on 30 Dec 2020.
96 Since then, SARS-CoV-2 has erupted into a global pandemic, resulting in approximately 15
97 million cases and more than half a million deaths in less than 8 months.⁴

98
99 The emergence and spread of SARS-CoV-2 has required a global response to mitigate the fallout
100 from the pandemic. As a result, the highest priorities for governments around the world are
101 prevention, treatment, and monitoring of infection and immunity.⁵ Understanding and
102 monitoring immune responses to SARS-CoV-2 is critical for development of antibody-based
103 therapeutics and vaccines. Both are challenging to study at the necessary scale due to the
104 inherent danger of working with live virus and limited access to high level biosafety containment
105 facilities (i.e. BSL3). However, the development of pseudotyped viral particles capable of
106 recapitulating SARS-CoV-2 entry—without the dangers or limitations of working with live
107 virus—addresses these concerns. Many such pseudotype virus (PsV) systems based on lentivirus

108 or vesicular stomatitis virus backbones have been published.⁶⁻⁹ These PsV systems have been
109 used to understand and assess humoral immunity in acute and recovered COVID-19 patients, and
110 to screen for therapeutic entry inhibitors, such as small molecules, monoclonal antibodies, or
111 convalescent sera. Most importantly, such a surrogate BSL2 virus neutralization assay (VNA) is
112 needed to screen for vaccine induced responses, in domestic animals and humans, as the world
113 rushes to develop candidate vaccines against SARS-CoV2.

114
115 As of this writing, at least five SARS-CoV-2 vaccine developers have reported Phase I/II results
116 involving over 1700 participants.¹⁰⁻¹⁵ While each group claims promising results, it is difficult to
117 compare vaccine induced immune responses between the various vaccine platforms. This is not
118 only due a lack of a standardized reporting but also due to a lack of standardized assays for
119 reporting virus neutralization titers. Furthermore, at least 16 studies have reported 350 patients
120 receiving convalescent plasma therapy for COVID-19. Across all 16 plasma studies, some
121 groups establish enzyme-linked immunosorbent assays (ELISA) or live virus neutralization
122 thresholds to screen donor plasma , while others do not report binding or neutralization data.¹⁶⁻³³
123 Notably, none of these studies report using a PsV VNA to screen donor plasma. These
124 discrepancies in screening methods/metrics limit the ability to compare across groups and make
125 it difficult to draw conclusions about the quality/potency of antibody transferred to the
126 recipient.^{32,33}

127
128 A standardized virus neutralization assay (VNA) that provides robust, high-throughput results
129 (>100,000 infections/week), is easily “kit-able”, and generates absolute virus neutralization titers
130 (VNT), would allow for meaningful comparisons across different labs. In addition to helping

131 down-select the myriad vaccine candidates, use of a standardized VNA to report VNT in
132 absolute units can crowd-source the immense effort being expended by multiple labs across the
133 globe to better understand the basis of the marked variation in VNT seen in COVID-19
134 recovered patients.^{34,35}
135
136 The SARS-CoV-2 spike glycoprotein (S) is embedded in the viral envelope and facilitates both
137 receptor recognition and membrane fusion. SARS-CoV-2-S is 1273 amino acids in length and,
138 like other coronaviruses, is a trimeric class I fusion protein.³⁶ The S glycoprotein contains two
139 subunits, the N-terminal, S1 subunit and the C-terminal, S2 subunit. The S1 subunit contains the
140 receptor-binding domain (RBD), which is responsible for host receptor binding. The S2 subunit
141 contains the transmembrane domain, cytoplasmic tails, and machinery necessary for fusion,
142 notably the fusion peptide and heptad repeats.^{37,38} Angiotensin-converting enzyme 2 (ACE2), a
143 cell surface enzyme in a variety of tissues, facilitates binding and entry of SARS-CoV-2.³⁹⁻⁴¹
144 However, ACE2 alone is not sufficient for efficient entry into cells. While entry depends on the
145 S1 subunit binding ACE2, entry is further enhanced by proteolytic cleavage between the S1/S2
146 and S2' subunits. For both SARS-CoV-1 and SARS-CoV-2, this cleavage-mediated activation of
147 S-mediated entry is supported by the expression of cell-associated proteases, like cathepsins or
148 transmembrane serine protease 2 (TMPRSS2), or the addition of exogenous proteases that mimic
149 the various trypsin-like proteases present in the extracellular lung milieu.^{39,42-51} These proteases
150 facilitate entry at the cell surface or via an endosomal route in a cell-type dependent manner.
151 Extracellular proteases are thought to play a pathophysiological role in the lung tissue damage
152 caused by unabated MERS-CoV, SARS-CoV-1, and likely SARS-CoV-2 replication.^{49,50} Thus,

153 in order to represent SARS-CoV-2 cell entry faithfully, a viral neutralization assay (VNA) must
154 be sensitive not only to ACE2 binding but also to the proteolytic activation of spike.

155

156 In addition to its role in receptor binding and entry, S is the primary surface glycoprotein and is
157 the major target of the neutralizing antibody response.⁵²⁻⁵⁶ Patients infected with SARS-CoV-2
158 typically seroconvert within two weeks of symptom onset, with about half developing antibodies
159 within 7 days.⁵⁷⁻⁵⁹ Antibody titers appear to be durable at greater than 40 days post infection,⁵⁸
160 but in the case of SARS-CoV-1, reductions in IgG positive titers begin around 4-5 months post
161 infection and show a significant drop by 36 months.⁶⁰ Although there are reports of SARS-CoV-
162 2 infected individuals testing positive by RT-PCR weeks after being confirmed as recovered by
163 two consecutive negative tests, these are more likely the result of false negatives than of
164 reinfection.^{61,62} Multiple groups have shown that fully recovered rhesus macaques previously
165 infected with SARS-CoV-2 are refractory to reinfection, at least within four weeks of the
166 primary challenge.^{63,64} However, a better understanding of the durability and efficacy of the
167 neutralizing antibody response in patients previously infected with SARS-CoV-2 is of paramount
168 importance. Not only do IgG titers wane in the case of SARS-CoV-1, but reinfection is possible
169 in other endemic human coronaviruses (HCoV) such as 229E, NL63, and OC43 in as little as a
170 year.⁶⁵⁻⁶⁷ Whether the waning of neutralizing SARS-CoV-2 antibodies impacts susceptibility to
171 re-infection is an urgent question that needs to be answered by longitudinal follow-up studies.⁶⁸⁻

172 ⁷¹

173

174 Humoral immune responses to the SARS-CoV-2 S protein are typically evaluated by ELISAs
175 and its many variants (CLIA, LFA, etc.). These serological binding assays rightfully play a

176 central role in determining patient antibody responses and can complement diagnostics and sero-
177 epidemiological studies, especially when combined with antibody subclass determination (IgM,
178 IgA and IgG).^{72–74} Nonetheless, as many antibodies generated to the spike protein bind but do not
179 block virus entry,^{75–78} ELISA-based assays that detect titers of spike-binding antibodies cannot
180 always correlate perfectly with neutralizing antibody titers as measured by plaque reduction
181 neutralization or microneutralization tests.^{74,79–82} Even a cleverly designed competitive ELISA
182 set up to detect antibodies that block the binding of RBD to ACE2^{76,83} cannot capture the
183 universe of neutralizing antibodies targeted to a conformationally dynamic trimeric spike on a
184 virion.^{84,85} The gold standard for detecting antiviral antibodies remains the virus neutralizing
185 assay. Assays that faithfully recapitulate entry of SARS-CoV-2 while maximizing safety, speed,
186 and scalability will be vital in the coming months and years. They will enable monitoring of
187 patient neutralizing antibody response, efficacy of vaccines and entry inhibitors, and the
188 screening of convalescent plasma from COVID-19 recovered patients.^{57,86}

189
190 In order to meet this need while maximizing safety, speed, and scalability, we generated a
191 SARS-CoV-2 pseudotyped viral particle (CoV2pp) by using vesicular stomatitis virus bearing
192 the *Renilla* luciferase gene in place of its G glycoprotein (VSVΔG-rLuc). This approach has been
193 used safely by our group and others to study viruses that would otherwise require significant
194 biosafety constraints, including Ebola virus, Nipah virus, and, most recently, SARS-CoV-2.^{6,8,87–}
195 ⁹⁰ Here, we present a detailed protocol for the production of CoV2pp, characterize the
196 contributions of stable expression of ACE2 as well as endogenous or exogenous proteases on
197 entry, and standardize the production and performance characteristics of these CoV2pp for use in
198 a robust high throughput VNA. We have sent out our standardized CoV2pp as ready-to-use “out

199 of the box” VNAs, ≥ 1000 infections/request, to multiple labs across three continents. We show
200 here the validation of our CoV2pp in a standardized VNA by four independent groups spread
201 across two continents using sera samples from geographically distinct and ethnically diverse
202 cohorts. Lastly, we utilized our standardized CoV2pp and VSV-Gpp in a screen to identify two
203 ultra-permissive 293T cell clones that stably express either ACE2 alone or ACE2+TMPRSS2.
204 These isogenic cell lines support either the late (293T-ACE2) or early (293T-ACE2/TMPRSS2)
205 entry pathways that SARS-CoV-2 uses.^{40,45,50,91} These ultra-permissive 293T clones allow for
206 use of unpurified virus supernatant from our standard virus production batch, which can now
207 provide for ~150,000 infections per week (96-well format) with no further scale-up. In sum, we
208 have generated a standardized, scalable, high-throughput BSL2-compatible CoV2pp VNA that
209 can provide robust metrics (absIC50, absIC80, absIC90) for meaningful comparisons between
210 labs.

211

212

213 **Results:**

214

215 **Production of VSV Δ G-rLuc bearing SARS-CoV-2 spike glycoprotein**

216 Our initial objective was to produce SARS-CoV-2 PsV sufficient for $\geq 10,000$ infections/week at
217 $\sim 1:100$ signal:noise ratio when performed in a 96-well format. We settled on a VSV-based rather
218 than a lentiviral PsV system as lentiviruses are intrinsically limited by their replication kinetics
219 and particle production rate (10^4 - 10^6 /ml for lentiviruses versus 10^7 - 10^9 /ml for VSV without
220 concentration). We optimized the production of our VSV Δ G-rLuc pseudotyped viral particles
221 (pp) bearing the SARS-CoV-2 spike glycoprotein as diagramed in Figure 1A. A detailed
222 production protocol is given in Supplementary Methods. Notably, this protocol involves
223 infecting producer cells at a low multiplicity of infection (MOI) of stock VSV Δ G-G*, incubating
224 producer cells with an anti-VSV-G monoclonal antibody and generating the pseudotyped
225 particles in Opti-MEM media. The first two measures effectively eliminated the background
226 signal from residual VSV-G while the last measure allowed for more cleavage of SARS-CoV-
227 2pp in producer cells (Supplemental Figure 1). While others have shown that truncating the
228 cytoplasmic tail (CT) of SARS-CoV-2-S is typically required for greater functional incorporation
229 into heterologous viral cores,^{7,9,92,93} we chose to optimize pseudotyping with full-length SARS-
230 CoV-2 spike. CT truncations in many other class I viral fusion proteins, including other ACE2-
231 using coronaviruses (HCoV-NL63 and SARS-CoV-1) can affect ectodomain conformation and
232 function.⁹⁴⁻¹⁰³ Until such time that we gain a fuller understanding of SARS-CoV-2 entry, we felt
233 it was necessary to have a surrogate assay that reflects the biology of the full-length virus spike.

234

235 Following the protocol detailed in Supplementary Methods, we produced BALDpp, NiV-RBPpp,
236 CoV2pp, and VSV-Gpp using the VSV Δ G-rLuc reporter backbone and titered them on Vero-
237 CCL81 cells (Fig. 1B). High background problems have resulted in low signal:noise ratios when
238 using VSV-based PsV, especially for viral envelope proteins that do not mediate efficient entry.
239 Here we used two different negative controls, BALDpp and NiV-RBP, to show that we resolved
240 the background issue. BALDpp lacks any surface glycoprotein while NiV-RBPpp incorporates
241 the NiV receptor binding protein (RBP), which binds to the broadly expressed ephrin-B2 with
242 sub-nanomolar affinity.^{88,104} However, the NiV fusion (F) glycoprotein necessary for viral entry
243 is absent. NiV-RBPpp without NiV-F should not fuse and effectively serves as a stricter and
244 complementary negative control. Under the conditions shown, neither BALDpp or NiV-RBPpp
245 gives any background even at the highest concentration of virus particles used.

246
247 These constructs were used to infect Vero-CCL81 cells and, as expected, we observe an average
248 of <500 RLUs of entry with our BALDpp and NiV-RBPpp negative controls. These levels of
249 entry were comparable to the “cells only” signal, providing confidence in any infection signals
250 10-fold over background. Undiluted CoV2pp entry resulted in luciferase values of over 50,000
251 RLUs; greater than 100-fold over background BALDpp signals (Fig. 1B). VSV-Gpp gave
252 several logs higher infectivity as expected. Western blots of the producer cells demonstrated
253 effective expression of cleaved, SARS-CoV-2 spike glycoproteins (Fig. 1C, left panel). Cleaved
254 CoV-2 spike products (S1, S2, and S2’) all appear to be incorporated into the VSV Δ G
255 pseudotyped particles (Fig. 1C, right panel). To ensure that entry of CoV2pp is SARS-CoV-2
256 spike-mediated, we show that the homologous soluble spike receptor binding domain (sRBD)
257 competitively inhibits our CoV2pp (Fig. 1D).

258

259 **CoV2pp entry is enhanced by trypsin treatment and spinoculation**

260 Next, we sought to enhance the relative signal of our CoV2pp infections, which will effectively
261 increase the number of infections we can provide or perform per batch of CoV2pp. Trypsin
262 treatment is reported to enhance SARS-CoV-1 and SARS-CoV-2 entry.^{39,45} Thus, we treated
263 CoV2pp stocks with the indicated range of trypsin concentrations for 15 min at room
264 temperature (Fig. 2A). In order to mitigate the effects of trypsin-dependent cytotoxicity, we
265 added 625 μ g/mL of soybean trypsin inhibitor (SBTI) to all samples before titrating the trypsin-
266 treated CoV2pp onto Vero-CCL81 cells. CoV2pp treated with the highest concentration of
267 trypsin (625 μ g/mL) resulted in ~100-fold enhancement of entry (Fig. 2A), but this trypsin-
268 dependent enhancement was only apparent when comparing entry of undiluted trypsin-treated
269 CoV2pp. We observed a greater than 50-fold reduction in entry (RLUs) after a 10-fold serial
270 dilution, which nullified any entry enhancement effects of trypsin. Indeed, the role of trypsin in
271 enhancing SARS-CoV-2 entry has not been fully determined. Trypsin may be acting to prime
272 CoV2pp to facilitate better entry upon spike-receptor interactions and/or assist to proteolytically
273 activate spike protein at or after receptor binding.⁵⁰ We hypothesized that the remaining
274 uninhibited trypsin-dependent effect, which must be present at the highest trypsin concentration,
275 was inadvertently neutralized by diluting the trypsin-treated CoV2pp in Dulbecco's modified
276 Eagle Medium (DMEM) +10% fetal bovine serum (FBS), which is the standard infection media
277 for titrating CoV2pp. To test this hypothesis, we diluted CoV2pp and trypsin-treated CoV2pp
278 1:10 in three different media conditions before infecting Vero-CCL81 cells. For trypsin-treated
279 CoV2pp, dilution in DMEM alone (serum free media, SFM) produced the highest signal:noise
280 ratio, almost 1000-fold over BALDpp (Fig. 2B). As a result, we chose CoV2pp treated with

281 625 μ g/mL of TPCK-treated trypsin, then 625 μ g/mL of SBTI, diluted in SFM as our standard
282 treatment condition. Furthermore, spinoculation at 1,250rpm for 1hr enhanced entry 3-5 fold
283 (compare signal:noise in Fig. 2B to Supplemental Fig. 2).

284
285 Our above hypothesis suggests that the uninhibited trypsin-dependent enhancing effect was
286 acting at the point of infection when CoV2pp is interacting with the host cell receptor. To
287 investigate further, we spiked in additional SBTI onto cells at the time of infection using
288 particles produced under the standard treatment condition as above. We found that additional
289 SBTI ($\geq 25\mu$ g/mL) added directly to cells at the point of infection was able to inhibit trypsin-
290 dependent entry enhancement (Fig. 2C). The data suggest that some trypsin was not inhibited by
291 the first 625 μ g/mL of SBTI and enough remained to enhance entry at the point of infection (Fig.
292 2D).

293

294

295 **Entry of CoV2pp is independently enhanced by stable expression of ACE2 and TMPRSS2** 296 **in cells already permissive for SARS-CoV-2 entry and replication**

297 To further characterize the determinants of CoV2pp entry, we generated Vero-CCL81 cell lines
298 stably expressing human ACE2 or human TMPRSS2. Vero-CCL81 cells are already highly
299 permissive for SARS-CoV-2 entry and replication. We infected the indicated cells with CoV2pp
300 or trypsin-treated CoV2pp diluted in serum-free media (standard treatment) and observed
301 enhanced entry in both stable cell lines (Fig. 3A). However, the entry enhancement of trypsin-
302 treated CoV2pp in Vero-CCL81+TMPRSS2 overexpressing cells was subdued relative to
303 untreated CoV2pp. This suggests that the presence of exogenous trypsin during CoV2pp entry

304 can substitute, in part, for the role played by cell surface TMPRSS2, an endogenous protease
305 known to facilitate entry into physiological relevant cell types *in vivo*.¹⁰⁵ Fig. 3B shows that the
306 relationship between ACE2 and TMPRSS2 expression—with regard to their effect on enhancing
307 SARS-CoV-2 spike mediated entry—is not straightforward. As ACE2 itself is a substrate for
308 TMPRSS2, the right stoichiometry of receptor/protease expression appears to be the main driver
309 of entry efficiency rather than the absolute expression of one or the other. This issue will be
310 further examined in the last section.

311

312 **Standardizing the parameters that impact CoV2pp-based virus neutralization assay**

313 Having established that exogenous trypsin can serve as a physiologically relevant substitute for
314 endogenous proteases known to enhance entry of CoV2pp, such as TMPRSS2, we sought to
315 characterize the parameters that might affect the performance our CoV2pp VNA. Conditions
316 tested included heat-inactivation of sera and the infection media used to dilute human sera
317 samples. We used representative spike ELISA positive or negative sera to serve as positive and
318 negative controls, respectively. When first diluted in SFM, we observed that negative sera can
319 have alarming amounts of neutralizing activity that appeared specific for CoV2pp as the same
320 sera did not neutralize VSV-Gpp entry (compare Supplemental Figures 3A with 3B, right panel).
321 This CoV2pp serum neutralizing factor is somewhat reduced but not completely diminished by
322 heat inactivation for 1hr at 56°C. Notably, the effect of this neutralizing factor from negative sera
323 was preempted by diluting the trypsin treated CoV2pp in DMEM containing 10% FBS
324 (Supplemental Fig. 3B). Importantly, recombinant sRBD neutralization was not affected by the
325 dilution of CoV2pp in Serum Free Media or DMEM+10% FBS (Supplemental Fig. 3C). The
326 nature of this factor that appears to inhibit spike-mediated entry is the subject of a concurrent

327 manuscript in submission (see Discussion). Regardless, for standardizing our CoV2pp-based
328 VNA, all subsequent patient sera were heat inactivated for at least 30 mins prior to use and
329 serially diluted in DMEM + 10% FBS, which also served as our infection media. Despite our
330 data from Fig. 2 implicating a trypsin-inhibitor-like activity in FBS, the marked inhibition of
331 CoV2pp entry by seronegative human sera is a greater limiting factor that prevents the robust
332 determination of true SARS-CoV-2 Nab titers. To achieve the same signal:noise ratio while
333 performing our VNA in the presence of 10% FBS, we increased the concentration of CoV2pp
334 used per infection.

335

336 **Performance characteristics of our standardized CoV2pp virus neutralization assay**

337 An initial set of sera for validation of CoV2pp VNA was generously provided by Dr. Florian
338 Krammer. These sera were screened according to a previously described two-stage ELISA
339 protocol in which 1:50 dilutions of patient sera were first screened for reactivity against sRBD.
340 Subsequently, the presumptive RBD-positive patient sera were used to assess reactivity to the
341 trimer stabilized ectodomain of spike at five different dilutions (1:80, 160, 320, 960, and
342 2880).^{73,106} These samples were used for neutralization studies with CoV2pp (Fig. 4A and 4B).
343 From the 36 patient sera tested, 6 were found to be negative for SARS-CoV-2 spike binding in
344 the ELISA described above. All of those 6 sera samples also showed no neutralization of
345 CoV2pp. The remaining 30 spike positive sera had 50% neutralizing titers that span 2 orders of
346 magnitude (Fig. 4B, 160 – 10,240). For a more quantitative assessment, we determined the total
347 IgG and IgM spike binding activity (ELISA AUC as described in Methods) of a representative
348 subset of fifteen sera samples and compared them with their reciprocal absIC₅₀ and absIC₈₀
349 values calculated from the CoV2pp neutralization curves (Fig.4A) as described in Methods.

350 Spike binding antibodies (IgG+IgM ELISA AUC) demonstrated a significant, positive
351 correlation with neutralizing antibody (nAb) titers (reciprocal absIC₅₀ and absIC₈₀) as
352 determined by our CoV2pp VNA (Fig. 4C, green circles). Moreover, these Nab titers against
353 CoV2pp also correlated well with live virus microneutralization titers (MN absIC₅₀, MN
354 absIC₈₀) (Fig. 4C, brown triangles). Full neutralization curves for the MN titers are shown in
355 Supplemental Figure 4. AbsIC₈₀ appeared to be a more stringent measure of nAb activity, as
356 some sera that have respectable MN absIC₅₀ titers never achieve an absIC₈₀ (Fig. 4C, bottom
357 graph, brown triangles on the x-axis). In this respect, the CoV2pp VNA has a larger dynamic
358 range and was more sensitive in its ability to sort out sera samples that can reach their respective
359 absIC₈₀ values. Notably, we find that sera samples with potent absIC₅₀ titers do not always
360 display potent absIC₈₀ values (Fig. 4D).

361

362 **Independent validation of our CoV2pp VNA with geographically distinct and ethnically** 363 **diverse COVID-19 patient cohorts**

364 To assess the robustness of our standardized CoV2pp VNA, we produced and distributed the
365 CoV2pp to many labs who have requested our assay for use in various screens for nAbs. Here,
366 we analyze and present the raw virus neutralization data provided to us by three independent
367 groups at the Icahn School of Medicine at Mount Sinai (ISMMS-2), Louisiana State University
368 Health Sciences Center Shreveport (LSUHS), and Argentina (COVIDAR). In sera or plasma
369 neutralization studies, these groups also observe similar absIC₅₀, absIC₈₀, and absIC₉₀
370 distributions. The LSUHS and ISMMS-2 cohorts represent data from 25 and 28 seropositive as
371 well as 10 and 11 seronegative samples, respectively, while the COVIDAR consortium assessed
372 neutralization from an initial set of 13 seropositive patient samples. For clarity, analysis of their

373 neutralization curves is presented as heatmaps in Fig. 5A similar to what was shown in Fig. 4B.

374 Full neutralization curves for each cohort are shown in Supplemental Figure 5.

375

376 The seronegative control samples from all groups revealed no CoV2pp neutralization. Rare, but

377 notable, seropositive samples from LSUHS also showed no neutralization (Fig. 5A, LSUHS).

378 ISMMS-2 performed their analysis on confirmed convalescent plasma donors.³² While all donors

379 had detectable nAb titers, their titers were highly variable and ranged across 2-3 logs. AbsIC80s

380 were calculated for all samples shown and we observed a moderate, but significant, positive

381 correlation between various spike ELISA metrics and absIC80 (Fig. 5B).

382

383 Aggregated reciprocal absIC80 from all three external labs as well as our own are shown in Fig.

384 5C. Notably, we observe a Gaussian distribution of reciprocal absIC80s from all groups (n=89).

385 The descriptive statistics from this aggregated data set reveals reciprocal absIC80 25th percentile

386 of 68.5, median of 170.8, and 75th percentile of 343.4. Descriptive statistics for reciprocal

387 absIC50 and absIC90 were also calculated and are reported in Supplemental Table 1. Using the

388 absIC80 descriptive statistics above and the ELISA endpoint titers from our initial 36 sera

389 samples, we observe that 0% of the samples displaying an ELISA endpoint titer of 320 have an

390 absIC50 greater than the median IC50. Perhaps not surprisingly, over 90% of samples with

391 ELISA endpoints of 2880 have IC50s at or beyond the 75th percentile (Table 1, represented

392 graphically in Supplemental Figure 6). Although absIC80 also generally follows this trend, we

393 once again note differences in the ranked order of absIC50 and absIC80 values calculated for all

394 sera samples (Supplemental Figure 7). This difference is more pronounced when comparing the

395 absIC50 and absIC90 graphs further highlighting the need for a neutralization assay with a broad

396 dynamic range. Additionally, the samples from each of the 4 groups show no statistical
397 difference when absIC50, 80, or 90 calculations are compared (Supplemental Figure 8).
398 Altogether, these data support the robustness of our CoV2pp VNA and suggest that absIC80 is a
399 more stringent and meaningful measure of Nab titers.

400

401 **Ultra-permissive 293T-ACE2 and 293T-ACE/TMPRSS2 clones allow for use of CoV2pp in** 402 **VNA at scale**

403 Although our standardized VNA appears robust, the requirement for exogenous trypsin and
404 spinoculation to achieve the optimal signal:noise limits the scalability of our VNA. Therefore,
405 we used our untreated CoV2pp to screen for ultrapermissive cell lines that would allow for our
406 CoV2pp VNA to be performed with dilutions of virus supernatant without any trypsin treatment,
407 virus purification, or spinoculation.

408

409 We generated three different 293T cell lines stably expressing ACE2 and/or TMPRSS2 via
410 lentiviral transduction. We then infected these cells with CoV2pp. Increased expression of
411 TMPRSS2 alone (293T-TMPRSS2) did not significantly improve entry (Fig. 6A), likely due to
412 the low to undetectable ACE2 expression levels (Fig. 6B, lanes 1 and 3). However, expression of
413 ACE2 significantly increased the entry of CoV2pp, which was further increased in 293T-
414 ACE2+TMPRSS2 cells, suggesting the synergistic activity of TMPRSS2 and ACE2 (Fig. 6A).
415 Western blot analysis confirmed the increased expression of ACE2 in the singly and doubly
416 transduced 293T cells (Fig. 6B). Additionally, increased expression of both ACE2 and
417 TMPRSS2 was confirmed by qPCR (Supplemental Fig. 9B). Interestingly, ACE2 expression
418 appeared to be decreased by >50% in 293T-ACE2+TMPRSS2 cells relative to 293T-ACE2 cells.

419 These observations highlight the complex roles that receptor binding and protease activation play
420 in SARS-CoV-2 entry, especially since ACE2 is a known substrate for TMPRSS2,¹⁰⁷ and
421 TMPRSS2 is also known to undergo autocatalytic cleavage.¹⁰⁸

422
423 Given how TMPRSS2 can enhance ACE2 dependent virus entry in a non-linear fashion, we used
424 BALDpp, CoV2pp, and VSV-Gpp to screen 19 single cell clones derived from 293T-ACE2 or
425 293T-ACE2+TMPRSS2 or Vero-ACE2 bulk transduced cells. The latter (Fig. 3) served as an
426 additional control in a naturally permissive cell line for SARS-CoV-2 entry and replication. All
427 three bulk transduced cell lines resulted in significant increases in entry of CoV2pp relative to
428 the parental 293T and Vero CCL81 cells (Supplemental Fig. 9 and Fig. 6C). However, only a
429 subset of the single cell clones performed better than bulk transduced cells. This is especially
430 notable in single cell clones derived from 293T-ACE2+TMPRSS2 parentals, where only two of
431 eight single cell clones show greater entry than the bulk transduced cells (Fig. 6C). One
432 particular clone, F8-2 (Fig. 6C) showed a nearly ten-fold increase in CoV2pp entry relative to the
433 bulk transduced cells. Using F8-2 to titer untreated CoV2pp without spinoculation, we observed
434 a dramatic increase in signal:noise relative to Vero-CCL81 WT cells and even the most
435 permissive 293T-ACE2 clone 5-7 (Supplemental Figure 10) such that RLU signals were
436 consistently 100-200 fold over BALDpp even at 1:50 dilution. TMPRSS2 was determined to be
437 the main driver of this entry enhancement in the F8-2 cells as treatment with Nafamostat, a
438 serine protease inhibitor, potently inhibited entry. However, this entry inhibition plateaued at
439 90% of maximal infection and the remaining 10% is nearly equivalent to the raw RLU values
440 seen with bulk 293Ts stably expressing ACE2 alone (Fig. 6D and Supplemental Figure 9),
441 suggesting a TMPRSS2-independent mechanism of entry. Entry into 293T-ACE2 cells was not

442 inhibited by Nafamostat, once again highlighting that CoV2pp can enter by both the early and
443 late entry pathways that have differential protease requirements.

444

445 **Diverse cell lines maintain similar kinetics in CoV2pp viral neutralization assays:**

446 We identified sera samples from 15 patients shown in Fig. 4A and tiered them into three groups:
447 negative for CoV2pp neutralization (negative), weakly positive for CoV2pp neutralization (low
448 positive), or strongly positive for CoV2pp neutralization (high positive) (Fig. 7A). We then
449 pooled equal volumes of each set of samples and performed CoV2pp neutralization assays on
450 Vero-CCL81 WT, 293T-ACE2 clone 5-7, 293T-ACE2+TMPRSS2 bulk transduced, and the
451 293T-ACE2+TMPRSS2 clone F8-2. We demonstrated that even in the case of varying levels of
452 ACE2 and TMPRSS2 expression, CoV2pp neutralization assays show consistent patterns of
453 neutralization, exhibiting the robust nature of the assay in tandem with its sensitivity in detecting
454 relative differences in neutralizing titer (Fig. 7B). Patterns of neutralization as well as the
455 calculated absIC50 and absIC80 reveal a large dynamic range between low and high neutralizing
456 patient sera across cell lines (Fig. 7B).

457

458 **Discussion**

459

460 Here, we present detailed and optimized protocols for producing VSVΔG pseudotyped viral
461 particles bearing SARS-CoV-2 spike protein. These CoV2pp recapitulate the SARS-CoV-2 entry
462 requirement for ACE2 expression on the host cell and enhanced infectivity in the presence of
463 activating proteases such as trypsin and/or TMPRSS2 in both 293T and Vero cells. Evidence
464 from our original standard condition suggested that only a minor fraction of the trypsin added

465 was required, and this trypsin acted at the level of receptor binding on the host cell (Fig. 2C and
466 D). Due to the observed effect of trypsin at the point of infection, we hypothesize that interaction
467 with a cellular factor, likely ACE2, induces conformational changes necessary for further
468 protease-mediated activation, likely at the S2' cleavage site, of SARS-CoV-2 spike. Moreover, in
469 a competitive inhibition assay, entry by the trypsin-treated CoV2pp was successfully inhibited by
470 sRBD. This faithful recapitulation of the entry processes previously described for SARS-CoV-1
471 and SARS-CoV-2 suggests that the trypsin treated CoV2pp represent a biologically relevant
472 system for identifying cells that support SARS-CoV-2 entry and for screening for entry
473 inhibitors, especially neutralizing antibodies or patient sera.

474
475 Prior to the use of trypsin-treated CoV2pp for neutralization experiments, we assessed how heat
476 inactivation of sera and different cell media affect neutralization. Here, we report detectable
477 neutralization by negative patient sera, which was previously reported in mouse and human sera
478 by Nie et al.⁸ However, it is unclear whether the sera used by Nie et al was heat inactivated. Our
479 observations also raise questions concerning the role the previously mentioned heat-labile serum
480 factor might play *in vivo*. We have shown that the CoV2pp VNA displays high sensitivity to the
481 inhibition of protease-mediated entry enhancement by human serum, FBS, SBTI, and even
482 Nafamostat when the protease in question is TMPRSS2. The inhibitory potential of human serum
483 implies a potential role serum factors could play in SARS-CoV-2 pathogenicity, tissue
484 restriction, and systemic spread in previously SARS-CoV-2 naïve patients (manuscript in
485 submission). These findings led to the establishment of heat inactivation of sera and use of
486 DMEM+10% FBS as conditions for trypsin-treated CoV2pp neutralization experiments. When
487 used for viral neutralization assays with patient sera, the absIC₅₀/absIC₈₀ against CoV2pp

488 correlated strongly with full-length spike ELISAs and live virus microneutralization titers.
489 Moreover, we have produced several batches of our CoV2pp and shipped them (along with
490 Vero-CCL81 cells) to many other groups as an “out-of-the-box” neutralization assay. The first
491 three groups to receive these particles, and who have volunteered their data, have successfully
492 screened patient sera with our assay and observed moderate but significant correlations to spike
493 ELISAs.

494
495 While ELISAs provide valuable information about epitopes recognized by individual samples
496 and antibody quantities, functional studies allow for more in-depth analyses of neutralization
497 potential. Notably, RBD-binding antibodies, particularly those that can inhibit ACE2 binding,
498 have received a large amount of attention. However, recent studies identifying non-RBD
499 binding—yet still neutralizing—antibodies, lend insight into novel neutralization mechanisms
500 and further highlight the importance of functional neutralization assays.^{84,85} Moreover, our
501 standardized CoV2pp VNA has a large dynamic range that can generate robust neutralization
502 curves, which allows for the calculations of more stringent metrics such as absIC50/absIC80.
503 AbsIC50/absIC80 give a more meaningful description of the neutralization potential of a given
504 serum sample as many patient sera (and potentially vaccine sera) may not even achieve an
505 absIC80. Reporting such standardized metrics will allow more meaningful comparisons of
506 vaccine elicited humoral responses, as well as the neutralization potential of convalescent sera,
507 especially when the latter is used for convalescent plasma therapy. This is of particular
508 importance given the widely variable ratios of spike ELISA binding values and neutralizing
509 antibody titers in comparisons of patients infected by SARS-CoV-2 and patients receiving
510 vaccines for SARS-CoV-2.¹³

511
512 Early reports of convalescent sera therapies show a tolerable safety profile and modest benefits
513 from this therapeutic approach.^{17,20,29,31–33,109} However, many of these trials only consider ELISA
514 neutralization titers and utilize extremely variable ELISA endpoint titers from not
515 reported/available to ranging from 1:40 to >1:1350. Interestingly, one pre-peer reviewed study
516 incorporated functional neutralization studies by utilizing trypsin-treated live virus to screen for
517 sera with >1:80 microneutralization titers on Vero E6 cells.³³ Given the wide variance in ELISA
518 titers as well as in virus neutralization titers, we believe convalescent plasma therapy will be
519 enhanced if patient sera are functionally screened and limited to only those displaying potent
520 neutralization titers. This will have the benefit of only transfusing patients with convalescent sera
521 that have a strong likelihood of substantial *in vivo* inhibitory potential, which is of particular
522 importance given the volumes transfused relative to a patient's total blood volume. Given our
523 results, a reasonable threshold might be a VNA-derived reciprocal absIC80 of ≥ 343.3 (i.e. ≥ 75 th
524 percentile).

525
526 Lastly, we utilize the CoV2pp system to screen 19 single cell clones and identify two single cell
527 clones of interest. These clones (293T-ACE2 clone 5-7 and 293T-ACE2+TMPRSS2 clone F8-2)
528 both support effective viral entry in the absence of trypsin and spinoculation and can be used for
529 scaling up viral neutralization assays. The ultra-permissive 293T-ACE2+TMPRSS2 F8-2 clone
530 in particular can support the use of a standardized VNA at the scale needed for screening entry
531 inhibitors, vaccine samples, donor plasma, etc. Our standardized CoV2pp production lot from a
532 single lab at 30x 10-cm dishes was sufficient for ~12,000 infections/week when performed in a
533 96-well format. The trypsin-treated CoV2pp (diluted 1:4) gives 100:1 signal:noise ratio when

534 performed in a 100 µl infection volume on Vero-CCL81 cells with spinoculation. Using the
535 ultra-permissive F8-2 clone, a 1:50 dilution gives similar signal:noise without any trypsin
536 treatment or spinoculation. Thus, our weekly production lot becomes sufficient now for
537 ~150,000 infections/week, which is enough for generating full neutralization curves for ~4,600
538 to ~6,200 samples (assuming an 8-point dilution series performed in quadruplicates or triplicates,
539 respectively).

540
541 Several recently described systems including VSV encoding the SARS-CoV-2 spike gene^{9,110}
542 and lentiviruses pseudotyped to bear the spike protein,¹¹¹ are capable of serving as surrogate
543 assays for assessing viral neutralization by patient sera or monoclonal antibodies. The replication
544 competent VSV system is attractive but still relies on a truncated spike. We have not been able to
545 rescue one with the full-length tail, even in our F8-2 clone although we could rescue multiple
546 VSVs bearing various betacoronavirus spikes (all with truncated tails). Nonetheless, our
547 standardized CoV2pp based on the VSVΔG system presents many advantages including safety,
548 ease and speed-of-use, identity to full-length SARS-CoV-2 spike, versatility for studying spike
549 mutants, and a large dynamic range. First, the viral genome used in this system lacks a viral
550 glycoprotein, which limits the virus to single-cycle replication and mitigates concerns about viral
551 spread. Next, because of the efficient replication of VSV, this system can be used to further
552 interrogate SARS-CoV-2 entry in primary cells and allows for the detection of Renilla luciferase
553 (or the desired reporter gene) within 12-18 hours post infection. Additionally, the VSVΔG
554 system presented here represents viral entry in the absence of mutations or truncations for
555 enhanced fusogenicity and/or entry dynamics. Lastly, since a viral glycoprotein must be provided
556 in trans for every production, this system is not susceptible to mutations over several passages

557 and is not dependent on repeated, arduous rescue attempts for the study of naturally occurring
558 spike mutants or chimeric spike glycoproteins. These studies may prove beneficial as we
559 consider natural occurring spike mutations—described on platforms such as GISAID—and strive
560 to understand their influence on viral entry kinetics or the influence on escape from antibody
561 neutralization.

562
563 In sum, we present detailed and optimized protocols for the production of a BSL-2 -safe
564 VSV Δ G-rLuc pseudoparticle and use it to interrogate viral entry. More importantly, we present
565 several resources that we believe will be invaluable during this global pandemic. This includes
566 cell lines (particularly 293T-ACE2+TMPRSS2 and Vero-CCL81-TMPRSS2 cells), and CoV2pp
567 that are ready to use “out-of-the-box” for mechanistic studies of viral entry or to screen inhibitors
568 of viral entry. Our findings, resources, and proposed guidelines have implications for
569 standardizing viral neutralization assays, with particular importance for screening therapeutic
570 monoclonal antibodies, vaccine efficacy, and convalescent sera.

571 **Materials and Methods:**

572

573 **Plasmids**

574 ☐ SARS-CoV-2 spike is in a pCAGG backbone and expresses the codon optimized Wuhan-
575 Hu-1 isolate (NCBI ref. seq. NC_045512.2).

576 ☐ SARS-CoV-2 sRBD (NCBI GenBank MT380724.1 from Krammer lab) is in a pCAGG
577 backbone and expresses the codon optimized sequence from the Wuhan-Hu-1 isolate.
578 sRBD-His used for neutralization studies was generated from this construct.

579 ☐ VSV-G is in a pCAGG backbone and expresses wild type Indiana strain VSV-G
580 (Genbank: ACK77583.1).

581 ☐ ACE2 packaging construct (GeneCopoeia, cat no EX-U1285-Lv105) uses a CMV
582 promoter to express TMPRSS2 and bears a puromycin selection marker in the integrating
583 cassette.

584 ☐ TMPRSS2 packaging construct (GeneCopoeia, cat no EX-Z7591-Lv197) uses a CMV
585 promoter to express TMPRSS2 and bears a blasticidin selection marker in the integrating
586 cassette.

587 ☐ psPAX2 2nd generation lentiviral packaging plasmid (Addgene #12259) expresses HIV-1
588 Gag, Pol, and Pro proteins.

589 ☐ NiV-RBP is in a pCAGG backbone and expresses the HA-tagged codon optimized NiV
590 receptor binding protein.

591

592 All plasmids listed here are ampicillin resistant. These constructs were transformed into stellar
593 competent cells, grown in bacterial growth media containing carbenicillin, prepared using
594 Invitrogen's midiprep kit, and sequence verified prior to use for experiments.

595

596 **Maintenance and generation of cell lines**

597 Vero-CCL81 and 293T cells were cultured in DMEM with 10% heat inactivated FBS at 37°C
598 with 5% CO₂. VSV-G pseudotyped lentiviruses packaging ACE2 or TMPRSS2 expression
599 constructs were generated by using Bio-T (Bioland; B01-01) to transfect 293T cells with the
600 second-generation lentiviral packaging plasmid (Addgene; 12259), pCAGG-VSV-G, and the
601 desired expression construct (i.e. ACE2 or TMPRSS2). The media was changed the next
602 morning. Viral supernatant was collected 48 hours post transfection, clarified by centrifugation at
603 4000 rpm for 5mins, and aliquoted prior to storage at -80°C. Vero-CCL81 and 293T cells were
604 transduced in a 6-well plate with the prepared lentiviral constructs. Two days after transduction,
605 these cells were expanded into a 10cm plate and placed under selection with puromycin (for
606 ACE2 transduced cells) or blasticidin (for TMPRSS2 transduced cells). 293T and Vero-CCL81
607 cells were selected with 2 or 10µg/mL of puromycin, respectively. For blasticidin, 293T were
608 selected with 5µg/mL and Vero-CCL81 cells were selected with 15µg/ml. To generate ACE2
609 and TMPRSS2 expressing 293T cells, 293T-ACE2 cells were transduced with the VSV-G
610 pseudotyped lentivirus packaging TMPRSS2. These cells were subsequently selected with
611 5µg/mL blasticidin. Low passage stock of each cell line generated were immediately frozen
612 down using BamBanker (Fisher Scientific; NC9582225). Single cell, isogenic clones were
613 isolated via serial dilution in a 96 well plate. Wells with only a single cell were grown up and
614 eventually expanded while under selection.

615

616 **Pseudovirus production and titering**

617 We provide detailed production and titering protocols in the supplementary text (Supplementary
618 Methods). Briefly, 293T producer cells were transfected to overexpress SARS-CoV-2 or VSV-G
619 glycoproteins. For background entry with particles lacking a viral surface glycoprotein, pCAGG
620 empty vector was transfected into 293T cells. Approximately 8 hours post transfection, cells
621 were infected with the VSV Δ G-rLuc reporter virus for 2 hours, then washed with Dulbecco's
622 phosphate-buffered saline (DPBS). Two days post infection, supernatants were collected and
623 clarified by centrifugation at 1250 rpm for 5mins. Upon collection, a small batch of VSV Δ G-
624 rLuc particles bearing the CoV2pp were then treated with TPCK-treated trypsin (Sigma-Aldrich;
625 T1426-1G) at room temperature for 15 minutes prior to inhibition with soybean trypsin inhibitor
626 (SBTI) (Fisher Scientific; 17075029). Particles were aliquoted prior to storage in -80°C to avoid
627 multiple freeze-thaws.

628

629 To titer these pseudoviruses, 20,000 Vero-CCL81 cells were seeded in a 96 well plate 20-24hrs
630 prior to infection. A single aliquot of BALDpp, CoV2pp, and VSV-Gpp were used for infections
631 and titrations were performed in technical triplicates. At 18-22 hours post infection, the infected
632 cells were washed with DPBS, lysed with passive lysis buffer, and processed for detection of
633 Renilla luciferase. The Cytation3 (BioTek) was used to read luminescence. Additional details
634 can be found in Supplementary Methods.

635

636 **Collection of producer cells and concentration of pseudotyped particles**

637 Cell lysates were collected from producer cells with 10mM EDTA in DPBS. Cells were
638 subsequently lysed with radioimmunoprecipitation assay (RIPA) buffer (Thermo Scientific,
639 89900) containing protease inhibitor (Thermo Scientific, 87785) for 30 minutes on ice. Lysates
640 were centrifuged at $25,000 \times g$ for 30 minutes at 4°C , and the supernatants were collected and
641 stored at -80°C . Total protein concentrations were determined by the Bradford assay. For viral
642 pseudoparticles, 10 mL of designated viral particles was concentrated via 20% sucrose cushion
643 (20% sucrose in DPBS), Amicon Ultra centrifugal filter (100 kDa cutoff, Millipore Sigma,
644 UFC910024), or PEG precipitation (Abcam, ab102538). Concentrated viral particles were
645 resuspended in $300\mu\text{L}$ of PBS or Opti-MEM for further analysis.

646

647 **Western blots**

648 All protein samples were run under reduced conditions by dilution in 6X SDS containing
649 dithiothreitol (DTT) and 5% beta-mercaptoethanol (Fisher Scientific; ICN19483425). The
650 protein was subsequently incubated in a heating block at 95°C for 15mins, run on a 4-15% SDS-
651 PAGE gel, and transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad).
652 Membranes were blocked with phosphate-buffered saline blocking buffer (LI-COR, 927-
653 700001), and then probed with the indicated antibodies. Antibodies against SARS-CoV2 (2B3E5
654 from Dr. Thomas Moran and GTX632604 from GeneTex), ACE2 (66699-1-Ig from Proteintech
655 and Rb ab108252 from abcam), VSV-G (A00199 from Genescript), VSV-M (EB0011 from
656 Kerast), anti-HA (NB600-363 from Novus), and CoX IV (926-42214 from LI-COR) were
657 used. For secondary staining, membranes were washed and incubated with the appropriate Alexa
658 Fluor 647-conjugated anti-mouse antibody or Alexa Fluor 647-conjugated anti-rabbit antibody.
659 Alexa Fluor 647 was detected using the ChemiDoc MP imaging system (Bio-Rad). Relative

660 ACE2 or TMPRSS2 abundance was calculated by first normalizing abundance relative to
661 GAPDH expression, then normalizing to wild type expression.

662

663 **RNA extraction and qPCR for ACE2 and TMPRSS2 expression**

664 Total RNA was extracted from cells using Direct-zolTM RNA Miniprep kit (Zymo, R2051), and
665 reverse transcription (RT) was performed with the TetroTM cDNA Synthesis kit (Bioline, BIO-
666 65043) and random hexamers. RT PCR was performed with the SensiFASTTM SYBR &
667 Fluorescein Kit (Bioline, BIO-96005). For qPCRs, HPRT forward (5'-
668 ATTGTAATGACCAGTCAACAGGG-3') and reverse (5'-GCATTGTTTTGCCAGTGTCAA-
669 3') primers, ACE2 forward (5'-GGCCGAGAAGTTCTTTGTATCT-3') and reverse (5'-
670 CCCAACTATCTCTCGCTTCATC-3') primers, and TMPRSS2 forward (5'-
671 CCATGGATACCAACCGGAAA-3') and reverse (5'-GGATGAAGTTTGGTCCGTAGAG-3')
672 primers were utilized. Samples were read on the CFX96 Touch Real-Time PCR Detection
673 System (Biorad). For qPCR forward and reverse primers were utilized. The qPCR was
674 performed in duplicates for each sample and results were calculated using $2^{-\Delta\Delta CT}$ with
675 normalization to the HPRT housekeeping gene control and further normalization to the 293T
676 parental cells.

677

678 **Sera acquisition**

679 All patient sera were acquired after approval by the respective institutional review boards and/or
680 equivalent oversight bodies (Bioethics Committee, Independent Ethics Committee) are indicated:
681 (1) Mount Sinai Hospital Institutional Review Board (New York, USA), (2) Louisiana State
682 University Health Sciences Center – Shreveport (LSUHS, Louisiana, USA), and (3) Fundacion

683 Instituto Leloir-CONICET, Universidad Nacional de San Martin, Laboratorio Lemos SRL,
684 Universidad de Buenos Aires (COVIDAR Argentina Consortium, Buenos Aires, Argentina).
685 Samples were de-identified at the source institutions or by the respective PIs of the IRB
686 approved protocols for sample collection before analysis performed in this study. All necessary
687 patient/participant consent has been obtained and the appropriate institutional forms have been
688 archived.

689

690 **ELISAs and Live Virus Neutralization**

691 Spike ELISAs for patient sera from the Krammer lab were performed in a clinical setting using
692 the two-step protocol previously published (Mount Sinai Hospital). Briefly, this involves
693 screening patient sera (at a 1:50 dilution) with sRBD and samples determined to be positive were
694 further screened at 5 dilutions for reactivity to spike ectodomain. All 36 samples were screened
695 in this manner, but a subset of 15 samples were further screened for IgG and IgM binding
696 antibodies to spike ectodomain. The protocol from Stadlbauer et al¹⁰⁶ was modified slightly to
697 start from a 1:300 and end at a 1:24300 dilution of sera. IgG and IgM antibodies were detected
698 with secondary antibodies conjugated to HRP (Millipore AP101P for anti-Human IgG and
699 Invitrogen A18841 for anti-Human IgM). Background was subtracted from the OD values,
700 samples were determined to be positive if ≥ 3 fold over the negative control and AUC was
701 calculated in PRISM. ELISAs performed by the LSUHS group utilized sRBD with a 1:50
702 dilution of patient sera to screen all samples followed by spike ectodomain with patient sera at a
703 1:100 dilution. Background subtracted OD values are reported for both sets of ELISAs. ELISAs
704 performed by the COVIDAR group utilized a mixture of sRBD and spike ectodomain for
705 samples serially diluted from 1:50 to 1:6400. AUC were calculated as described above.

706
707 All live virus neutralizations were performed at biosafety-level-3 (BSL-3) using the USA-
708 WA/2020 isolate of SARS-CoV-2 as described in Amanat et al⁷³. Briefly, ~600 50% tissue
709 culture infectious doses (TCID50) of virus was incubated with a serial dilution of patient sera for
710 1hr at 37°C prior to infection of Vero-E6 cells. Forty-eight hours post infection, cells were fixed
711 in 10% PFA and stained with mouse anti-SARS-CoV nucleoprotein antibody. This was
712 subsequently detected by the addition of HRP-conjugated goat anti-mouse IgG and
713 SIGMAFAST OPD. The BioTek Synergy 4 plate reader was used to measure OD490, which was
714 subsequently used to calculate microneutralization (MN) titers. The samples with live virus MN
715 titers were a part of a larger study by Krammer and colleagues looking at the longitudinal
716 dynamics of the humoral immune response. This study was recently posted on medRxiv.³⁵ We
717 obtained permission from the authors to utilize a random subset of sera samples from their study
718 and their associated MN titers for validation studies with our CoV2pp based virus neutralization
719 assay.

720
721 **Neutralization studies with patient sera, soluble RBD, or Nafamostat-mesylate**
722 De-identified sera were obtained with IRB approval to use for research purposes. Unless
723 otherwise noted, all patient sera were heat inactivated at 56°C for 30 minutes, and serially diluted
724 in DMEM+10%FCS when performing virus neutralization assays (VNAs). For groups receiving
725 our CoV2pp, we recommended titrating our stocks first to determine the linear dynamic range
726 that would be useful for VNAs done in their labs. As a quality control, we only send out CoV2pp
727 stocks that give signal:noise ratios of at least 100-fold over BALDpp when diluted 4-fold in 100
728 µl total infection volume in 96-well plate format. For the VNAs performed in our lab (ISMMS-

729 1), a pre-titrated amount of pseudotyped particles (diluted to give approximately 10^5 RLU) was
730 incubated with a 4-fold serial dilution of patient sera for 30 minutes at room temperature prior to
731 infection of Vero-CCL81 cells seeded the previous day. For sRBD or Nafamostat inhibition, a
732 pre-titrated amount of pseudotyped particle dilution was mixed with the protein or compound
733 and added to cells immediately after. Approximately 20 hours post infection, cells were
734 processed for detection of luciferase activity as described above. Our recommendations to
735 generate a robust neutralization curve were to do an 8-point serial dilution curve with each point
736 done in triplicate. Raw luminometry data were obtained from labs that volunteered VNA results
737 from at least 12 patient samples and analyzed as indicated below.

738
739 Method modifications from the three contributing labs are as follows. Serum neutralizations by
740 LSUHS (Kamil and Ivanov) were performed by first diluting 4-fold in 100 μ l total volume then
741 diluting via a 3-fold serial dilution. Cell lysates were transferred to a white walled 96 well plate,
742 then the Promega Renilla luciferase assay kit was utilized to detect luciferase. Plates were read
743 on a Tecan SPARK plate reader by collecting total luminescence signal for 10 seconds. ISMMS-
744 2 (Hioe) began neutralizations at a 10-fold dilution and proceeded with a 4-fold serial dilution.
745 Plates were read on a black walled 96 well plate using the Renilla Glo substrate (Promega,
746 E2720) with a 1 second signal integration time. COVID-19 samples were provided to ISMMS-2
747 by the Clinical Pathology Laboratory at ISMMS or from an IRB-approved study at the James J.
748 Peters VA Medical Center. COVIDAR (Gamarnik) began at either an 8-fold or 16-fold dilution
749 then continuing with either a 3-fold or 2-fold serial dilution respectively. White, F-bottom
750 Lumitrac plates (Greiner, 655074) plates were read via the GloMax® Navigator Microplate

751 Luminometer (Promega, GM200) using the ONE-Glo™ Luciferase Assay System (Promega,
752 E6110).

753

754 **Inhibitory Concentration Calculations and other R packages used**

755 Relative inhibitory concentrations (IC) values were calculated for all patient sera samples by
756 modeling a 4-parameter logistic regression with `drm` in the R `drc` package.¹¹² For examples, a
757 relative inhibitory concentration of 50% (IC₅₀) is calculated as the midway point between the
758 upper and lower plateaus of the curve. Absolute inhibitory concentration (absIC) was calculated
759 as the corresponding point between the 0% and 100% assay controls. For example, the absIC₅₀
760 would be the point at which the curve matches inhibition equal to exactly 50% of the 100% assay
761 control relative to the assay minimum (0%).¹¹³ As a result, sera samples that are non-neutralizing
762 or minimally neutralizing may have lower plateaus indicating they cannot reach certain absolute
763 inhibitory concentrations, such as an absIC₉₀ or absIC₉₉. R was also used to generate the
764 heatmaps presented in Fig. 4B and Fig. 5A as well as the plots in Fig. 4D, Fig. 5C, and
765 Supplemental Fig. 7.

766

767

768 **Acknowledgements**

769 In addition to the three labs that provided data for this paper, we acknowledge the generosity of
770 the many labs that independently verified our CoV2pp VNA. We want to especially
771 acknowledge the entirety of the Lee Lab, whom, during a pandemic, dropped all other work and
772 pooled resources together in pursuit of developing this and other tools that are providing support
773 to other labs doing COVID-19 work. Moreover, we acknowledge the generosity of the patients

774 that donated blood for use in convalescent sera studies and for further use in research studies
775 similar to the work presented here.

776

777 The authors acknowledge the following funding: KYO and CS were supported by Viral-Host
778 Pathogenesis Training Grant T32 AI07647; KYO was additionally supported
779 by F31 AI154739. SI and CTH were supported by postdoctoral fellowships from CHOT-SG
780 (Fukuoka University, Japan) and the Ministry of Science and Technology (MOST, Taiwan),
781 respectively. BL acknowledges flexible funding support from NIH grants R01 AI123449, R21
782 AI1498033, and the Department of Microbiology and the Ward-Coleman estate for endowing the
783 Ward-Coleman Chairs at the ISMMS. JPK and SSI acknowledge funding from a LSUHS
784 COVID-19 intramural grant. JPK and SSI acknowledge additional funding from NIH grants
785 AI116851 and AI143839, respectively. This work was further supported by the Microbiology
786 Laboratory Clinical Services at the Mount Sinai Health System and the Mount Sinai Health
787 System Translational Science Hub, NIH grant U54TR001433 to the Department of Medicine of
788 the ISMMS to SZP. We also acknowledge funding from the Department of Veterans Affairs
789 Merit Review Grant I01BX003860 (CEH, SZP, and JK), Research Career Scientist Award
790 1IK6BX004607 (CEH), and NIH grant AI139290 (CEH, SZP). We thank Randy A. Albrecht for
791 oversight of the conventional BSL3 biocontainment facility. Work in the Krammer laboratory
792 was partially supported by the NIAID Centers of Excellence for Influenza Research and
793 Surveillance (CEIRS) contract HHSN272201400008C (FK), Collaborative Influenza Vaccine
794 Innovation Centers (CIVIC) contract 75N93019C00051 (FK) and the generous support of the
795 JPB foundation, the Open Philanthropy Project (#2020-215611) and other philanthropic
796 donations.

797 **Figures/Figure Legends:**

798

799 **Figure 1. Production of VSV Δ G-rLuc bearing SARS-CoV-2 spike glycoprotein (A)**

800 Overview of VSV Δ G-rLuc pseudotyped particles bearing CoV-2 spike (top panel) with

801 annotated spike glycoprotein domains and cleavage sites (bottom panel). As mentioned in the

802 text, we refer to SARS-CoV as SARS-CoV-1 for greater clarity. **(B)** VSV- Δ G[rLuc]

803 pseudotyped particles (VSVpp) bearing the Nipah virus receptor binding protein alone (NiV-

804 RBPpp), SARS-CoV-2-S (CoV2pp), or VSV-G (VSV-Gpp) were titered on Vero-CCL81 cells

805 using a 10-fold serial dilution. Symbols represent the mean \pm SEM (error bars) of each titration

806 performed in technical triplicates. **(C)** Expression of the indicated viral glycoproteins on

807 producer cells and their incorporation into VSVpp. Western blots performed as described in

808 Methods using anti-S1 or anti-S2 specific antibodies. **(D)** CoV2pp entry is inhibited by soluble

809 receptor binding domain (sRBD) derived from SARS-CoV-2-S. CoV2pp and VSV-Gpp

810 infection of Vero-CCL81 cells was performed as in (B) in the presence of the indicated amounts

811 of sRBD. Neutralization curves were generated by fitting data points using a variable slope, 4-

812 parameter logistics regression curve (robust fitting method). The last point (no sRBD) was fixed

813 to represent 100% maximal infection. Each replicate from an experiment performed in duplicate

814 is shown. The calculated IC₅₀ for sRBD neutralization of CoV2pp is 4.65 μ g/mL.

815

816 **Figure 2. CoV2pp entry is enhanced by trypsin treatment. (A)** Optimizing trypsin treatment

817 conditions. Supernatant containing CoV2pp were trypsin-treated at the indicated concentrations

818 for 15 min. at room temperature prior to the addition of 625 μ g/mL of soybean trypsin inhibitor

819 (SBTI). These particles were then titered on Vero-CCL81 cells in technical triplicates. Data

820 shown as mean +/- SEM. **(B)** Dilution in serum free media (SFM, DMEM only) provides the
821 highest signal:noise ratio for trypsin-treated CoV2pp entry. Particles were diluted 1:10 in Opti-
822 MEM, SFM, or DMEM+10%FBS prior to infection of Vero-CCL81 cells and spinoculation as
823 described in Fig. 1D. Cells infected without spinoculation show approximately 3x less
824 signal:noise ratios (Supplemental Fig. 2). **(C)** Addition of soybean trypsin inhibitor at the time of
825 infection reduces trypsin treated particle entry. This was performed in technical triplicates for
826 two independent experiments. Shown are the combined results with error bars indicating SEM
827 and **** indicating a p-value <0.0001. **(D)** Schematic showing overall view of how protease
828 priming and SBTI treatment is working to enhance CoV2pp entry.

829

830 **Figure 3. Trypsin-treated CoV2pp depend on ACE2 and TMPRSS2 for entry.** **(A)** Parental
831 and TMPRSS2 or ACE2 transduced VeroCCL81 cells were infected with the indicated
832 pseudotyped viruses. All particles were diluted in serum free media in order to be within the
833 linear range for the assay. Normalized infectivity data is presented as fold-over Vero-CCL81-
834 WT for the various VSVpp shown. VSV-Gpp served as an internal control for the intrinsic
835 permissiveness of various cell lines to VSV mediated gene expression. Data is presented as mean
836 +/- SEM from two independent experiments done in technical triplicates. *, p <0.05, **, p-
837 <0.01, and ****, p <0.0001. **(B)** Western blot of wild type and transduced Vero CCL81 cells.
838 The numbers below each column show the relative ACE2 abundance was measured by
839 densitometry and normalized as described in Methods.

840

841 **Figure 4. CoV2pp viral neutralization assay and absIC50/80 versus spike binding of patient**
842 **sera.** **(A)** 36 patient sera screened for CoV2pp neutralization. CoV2pp were used to infect Vero-

843 CCL81 cells in the presence of a 4-fold serial dilution of patient sera as described in the
844 Methods. Samples in light purple do not neutralize CoV2pp. Neutralization curves were fit using
845 a variable slope, 4-parameter logistics regression curve with a robust fitting method. **(B)** The
846 same 36 samples are shown as a neutralization heat map, which were generated in R as described
847 in the Methods. Here, red represents complete neutralization and blue represents no
848 neutralization. Samples are sorted by the average from the first four dilutions with the most
849 neutralizing samples on the left. **(C)** Correlation of CoV2pp neutralization titers to spike binding
850 (ELISA AUC) and live virus microneutralization (MN) activity. Absolute IC₅₀ (absIC₅₀, top)
851 and IC₈₀ (absIC₈₀, bottom) for CoV2pp neutralizations and live virus MNs were calculated in R
852 using a 4-parameter logistic regression model as described in the Methods. Presented are the
853 added IgG and IgM ELISA AUC. AUC and live virus neutralizations were performed as
854 described in the Methods. Presented are the r and p value from a simple linear regression. **(D)**
855 Positive serum samples and their CoV2pp reciprocal absIC₅₀ (top) and absIC₈₀ (bottom). The
856 IC₅₀ graph is colored and ordered to display samples with low, average, or high IC₅₀ as blue,
857 grey or red circles, respectively. The IC₈₀ graph below retains the coloring from the IC₅₀ graph,
858 but the samples are now ordered from left to right to show samples with the lowest to highest
859 IC₈₀ values. Tukey box and whisker plots show median with interquartile range (IQR) and
860 whiskers extending to 1.5x the IQR. All points outside that range are depicted.

861
862 **Figure 5. CoV2pp viral neutralization assay validated against patient sera by external**
863 **groups. (A)** Patient sera neutralization of CoV2pp for 88 samples run by three different
864 independent groups. This is visualized as in Fig. 4B where red represents complete neutralization
865 and blue represents no neutralization. **(B)** Correlations of CoV2pp reciprocal AbsIC₈₀ to spike

866 ELISAs. AbsIC80 was calculated as previously described in Fig. 4C. For LSUHS ELISAs, spike
867 ectodomain was used and sera was diluted to a 1:100 dilution. For the COVIDAR ELISAs, a
868 mixture of sRBD and spike was utilized as previously described¹¹⁴ and AUC was calculated as
869 described in the Methods. (C) Summary AbsIC80 of 89 positive sera CoV2pp neutralizations.
870 Samples from all 4 groups are depicted on the X-axis. AbsIC80 was calculated as described in
871 Fig. 4C and Tukey box and whisker plots are shown as described in Fig. 4D.

872

873 **Table 1. Comparison of ELISA endpoint titers to CoV2pp neutralization.** Presented are the
874 clinical lab ELISA endpoint titers from samples discussed in Fig. 4A. Descriptive statistics were
875 generated in PRISM using data presented in Fig. 5C. Values highlighted in red are of interest and
876 are discussed further in the Results.

877

878 **Figure 6. 293T stably transduced with ACE2 and TMPRSS2 (293T-ACE2+TMPRSS2) are**
879 **ultra-permissive for SARS-CoV-2pp infection.** (A) Infection of 293T cells lines transduced to
880 stably express, TMPRSS2, ACE2, or both. Cell lines were generated as described in the
881 Materials and Methods. A single dilution of particles was used to infect cells prior to
882 spinoculation as described in the Methods. Infections were done in technical triplicates.
883 Presented are the aggregated results from two independent replicates and error bars show SEM.
884 For statistics, ns = not significant, ** is a p-value <0.01, and **** is a p-value <0.0001. (B)
885 Western blot of ACE2 expression in 293T cell lines. This was performed as described in the
886 methods and the values below each column represents the relative abundance of ACE2. (C)
887 Normalized CoV2pp entry into single cell clones. Entry was normalized to the wild type parental
888 cell line and further normalized to VSV-G entry. Presented are the average of one experiment in

889 technical triplicates. Error bars show the median and interquartile range. Raw entry data for each
890 cell clone is shown in Supplementary Fig. 9A (D) Entry inhibition of CoV2pp in by Nafamostat
891 mesylate, a serine protease inhibitor. Nafamostat was mixed with CoV2pp (left panel) or VSV-
892 Gpp (right panel) prior addition to cells. Shown are the results from one experiment in technical
893 triplicates. Data are presented as described in Fig. 4A and error bars show SEM.

894

895 **Figure 7. Ultra-permissive 293T-ACE2+TMPRSS2 cell clones retains the same phenotypic**
896 **sensitivity to convalescent COVID-19 sera.** (A) Selection of pooled sera samples. Results from
897 Fig. 4A are reproduced here for the reader's convenience. Presented are the subset of samples
898 that were pooled for use in viral neutralization assays (VNAs) in the adjacent panel. (B) Vero
899 CCL81 and transduced 293T cells were used for VNAs. Sera previously shown to be negative,
900 weakly positive, or strongly positive for CoV2pp neutralizations were selected to be pooled in
901 equal volumes. These were subsequently used for VNAs, which were performed and presented
902 as described in Fig. 4A. Notably, these VNAs were performed in the absence of exogenous
903 trypsin or spinoculation.

904

905 **Supplemental Table 1. Descriptive statistics for CoV2pp neutralizations across 4 groups.**

906 Presented are the descriptive statistics from the CoV2pp neutralizations shown in Fig. 5C.
907 Absolute IC₅₀, 80, and 90 were calculated as previously described in the Methods. Median and
908 other percentiles presented here were calculated in PRISM.

909

910 **Supplemental Figure 1. Expression spike glycoproteins in different growth media.**

911 Expression of CoV-2 spike in producer cells shows modestly increased cleavage in the presence
912 of reduced or absent FBS. Western blots performed as described in the Methods.

913

914 **Supplemental Figure 2. Dilution of CoV2pp in the absence of serum free media produces**

915 **the highest signal:noise for trypsin treated CoV2pp.** Performed as described in Fig. 2B, but

916 was done in the absence of spinoculation. Presented are the results from an experiment in

917 technical triplicate and error bars show the SEM.

918

919 **Supplemental Figure 3. Sera neutralization in the absence of 10% FBS and optimization of**

920 **neutralizations. (A)** Negative sera potently inhibits trypsin treated CoV2pp. CoV2pp were

921 diluted in serum free media (SFM), then pooled negative sera and a positive serum were used to

922 neutralize entry. An aliquot was heat inactivated (HI) for 1hr in a 56°C water bath prior to use.

923 Neutralizations were performed as described in the methods. Data are presented on a linear (left

924 panel) and log scale (right panel). Each replicate from one experiment in technical duplicates are

925 shown and neutralization curves were generated as done in Fig. 1D. **(B)** Sera neutralizations

926 were performed with untreated CoV2pp (left panel) or CoV2pp treated with trypsin (middle

927 panel). Both particles were diluted in DMEM+10% FBS and neutralization curves are presented

928 as described above. VSV-G was not neutralized by the negative or positive sera (right panel). **(C)**

929 sRBD neutralizes CoV2pp equivalently across all conditions tested. Data presented in Fig. 1D

930 (i.e. the untreated CoV2pp) is duplicated here. Neutralization curves are presented as described

931 above.

932

933 **Supplemental Figure 4. Live SARS-CoV-2 microneutralization curves.** Live virus
934 microneutralization curves were performed as described in the materials and methods.
935 Neutralizations were performed in technical duplicates and shown are SD. Data are presented as
936 in Fig. 4A and fit to a variable slope, 4-parameter logistics curve.

937
938 **Supplemental Figure 5. Neutralization curves from the LSUHS, ISMMS-2, and COVIDAR**
939 **labs.** The neutralization curves presented here were generated from the same data used to create
940 the neutralization heat maps shown in Figure 5A. The curves were fit using a variable slope, 4
941 parameter logistics model (robust regressions fitting). The ISMMS-2 group (top left panel) and
942 COVIDAR group (bottom panels) perform neutralizations in technical triplicates. The LSUHS
943 group (top right panel) performed their neutralizations in technical quadruplicates.

944
945 **Supplemental Figure 6. Relationship of ELISA endpoint titers and CoV2pp reciprocal**
946 **AbsIC50, 80, and 90.** Presented are the clinical lab ELISA endpoint titers and CoV2pp
947 neutralization absIC values. There are 11 samples with ELISA endpoints of 320, 8 samples with
948 ELISA endpoints of 960, and 11 samples with ELISA endpoints of 2880. Absolute (Abs) IC50,
949 80, and 90 were calculated as described in the Methods. Error bars (blue) show median and
950 interquartile range, red and black dotted lines represent the median and 75th percentile for each
951 AbsIC value as calculated in Supplemental table 1. The gray shaded region indicates samples
952 that fall above the 75th percentile. One sample with an ELISA endpoint of 320 has an absIC90
953 below 10^{-1} and thus is not present on the absIC90 graph.

954

955 **Supplemental Figure 7. Ordered CoV2pp absolute IC50 (top), IC80 (middle) and IC90**
956 **(bottom) plots from all four groups.** As previously presented in Fig. 4D, the IC50 graph is
957 colored and ordered to display samples with low, average or high IC50 as blue, grey or red
958 circles, respectively. The colors from the IC50 graphs are retained in the IC80 and IC90 graphs,
959 which are ordered from lowest to highest neutralization. Tukey box and whisker plots are
960 presented to the right of the graph. These show findings that are consistent to the observations in
961 Fig. 4D, suggesting that not all samples with high IC50s have potent IC80s or IC90s.

962
963 **Supplemental Figure 8. Comparison of CoV2pp Absolute IC values across all 4 groups.**
964 CoV2pp Absolute IC values were calculated as previously described in Fig. 4C. Shown are the
965 CoV2pp absolute IC50 (left panel), IC80 (middle panel) and IC90 (right panel) from all four
966 groups with error bars (blue) showing the median and interquartile range. The red dotted line
967 presents the median from the aggregated positive neutralization samples as reported in
968 Supplemental Table 1. The black dashed line indicates neat serum and the shaded gray region
969 highlights samples that fall below this value. An ordinary one-way ANOVA with Dunnett's
970 correction for multiple comparisons was performed for statistics. This analysis revealed no
971 statistically significant difference between the Absolute IC values obtained across the 4 groups.
972 There were notable outliers in this data set, including individuals that show poor neutralization
973 (i.e. the 3 samples in the IC50 plot from LSUHS) and an individual that showed exceptionally
974 potent neutralization (i.e. the sample in all plots from ISMMS-2). One sample from ISMMS-1
975 had an absIC90 below 10^{-1} and, as a result, is not presented on the absIC90 graph.

976

977 **Supplemental Figure 9. Screening and validation of single cell clones.** (A) Raw RLU values
978 from infection of the indicated cells by BALDpp, CoV2pp, or VSV-Gpp. Parental cell lines, bulk
979 transduced cell lines, and isogenic cell lines are indicated. Highlighted in blue and purple are the
980 ultra-permissive clones stably expressing ACE2 or ACE2 and TMPRSS2, respectively.
981 Presented are the results from an experiment in technical triplicates and error bars show the
982 SEM. (B) Expression of ACE2 and TMPRSS2 in select cell lines. RNA extraction and qPCR
983 performed as described in the Methods prior to calculating $2^{-\Delta\Delta CT}$, which was then normalized to
984 the 293T parental cells. Of interest are the clones highlighted in blue and purple, which were
985 transduced to stably express ACE2 or ACE2 and TMPRSS2.

986

987 **Supplemental Figure 10. CoV2pp were titered on Vero-CCL81 cells, 293T-ACE2 clone 5-7,**
988 **and 293T-ACE2-TMPRSS2 clone F8-2.** Titrations were performed with untreated CoV2pp and
989 without spinoculation. Presented are the results from technical triplicates and bars show the
990 SEM.

991 **References**

992

- 993 1. Rehman, S. U., Shafique, L., Ihsan, A. & Liu, Q. Evolutionary trajectory for the
994 emergence of novel coronavirus SARS-CoV-2. *Pathogens* **9**, 1–12 (2020).
- 995 2. Peiris, J. S. M., Guan, Y. & Yuen, K. Y. Severe acute respiratory syndrome. *Nat. Med.* **10**,
996 S88–S97 (2004).
- 997 3. Center for Disease Control. *Revised U.S. Surveillance Case Definition for Severe Acute*
998 *Respiratory Syndrome (SARS) and Update on SARS Cases - United States and Worldwide,*
999 *December 2003.* (2003).
- 1000 4. World Health Organization. *Novel Coronavirus (2019-nCoV): situation report, 19.*
1001 (2020).
- 1002 5. Petherick, A. Developing antibody tests for SARS-CoV-2. *Lancet* **395**, 1101–1102 (2020).
- 1003 6. Schmidt, F. *et al.* Measuring SARS-CoV-2 neutralizing antibody activity using
1004 pseudotyped and chimeric viruses. *J. Exp. Med.* **217**, (2020).
- 1005 7. Dieterle, M. E. *et al.* A Replication-Competent Vesicular Stomatitis Virus for Studies of
1006 SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. *Cell Host Microbe* (2020).
1007 doi:10.1016/j.chom.2020.06.020
- 1008 8. Nie, J. *et al.* Establishment and validation of a pseudovirus neutralization assay for SARS-
1009 CoV-2. *Emerg. Microbes Infect.* **9**, 680–686 (2020).
- 1010 9. Case, J. B. *et al.* Neutralizing antibody and soluble ACE2 inhibition of a replication-
1011 competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. *bioRxiv* (2020).
1012 doi:<https://doi.org/10.1101/2020.05.18.102038>
- 1013 10. Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. *N.*

- 1014 *Engl. J. Med.* (2020). doi:10.1056/NEJMoa2022483
- 1015 11. Folegatti, P. M. *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine
1016 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised
1017 controlled trial. *Lancet* 1–13 (2020). doi:10.1016/S0140-6736(20)31604-4
- 1018 12. Zhu, F. C. *et al.* Safety, tolerability, and immunogenicity of a recombinant adenovirus
1019 type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-
1020 in-human trial. *Lancet* **395**, 1845–1854 (2020).
- 1021 13. Mulligan, M. J. *et al.* Phase 1/2 Study to Describe the Safety and Immunogenicity of a
1022 COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age:
1023 Interim Report. *medRxiv* (2020). doi:10.1101/2020.06.30.20142570
- 1024 14. Sahin, U. *et al.* Concurrent human antibody and TH1 type T-cell responses elicited by a
1025 COVID-19 RNA vaccine. *medRxiv* (2020). doi:10.1101/2020.07.17.20140533
- 1026 15. Keech, C. *et al.* First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein
1027 Nanoparticle Vaccine. *medRxiv* 2020.08.05.20168435 (2020).
1028 doi:10.1101/2020.08.05.20168435
- 1029 16. Duan, K. *et al.* Effectiveness of convalescent plasma therapy in severe COVID-19
1030 patients. *Proc. Natl. Acad. Sci.* **117**, 9490–9496 (2020).
- 1031 17. Shen, C. *et al.* Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent
1032 Plasma. *JAMA* **323**, 1582 (2020).
- 1033 18. Li, L. *et al.* Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in
1034 Patients With Severe and Life-threatening COVID-19. *JAMA* **324**, 460 (2020).
- 1035 19. Joyner, M. J. *et al.* Early safety indicators of COVID-19 convalescent plasma in 5,000
1036 patients. *J. Clin. Invest.* (2020). doi:10.1172/JCI140200

- 1037 20. Joyner, M. J. *et al.* Evidence favouring the efficacy of convalescent plasma for COVID-19
1038 therapy. *medRxiv* 2020.07.29.20162917 (2020). doi:10.1101/2020.07.29.20162917
- 1039 21. Hartman, W., Hess, A. S. & Connor, J. P. Hospitalized COVID-19 patients treated with
1040 Convalescent Plasma in a mid-size city in the midwest. *medRxiv* (2020).
1041 doi:10.1101/2020.06.19.20135830
- 1042 22. Jin, C. *et al.* Treatment of Six COVID-19 Patients with Convalescent Plasma. *medRxiv*
1043 (2020). doi:10.1101/2020.05.21.20109512
- 1044 23. Rasheed, A. M. *et al.* The therapeutic effectiveness of Convalescent plasma therapy on
1045 treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad,
1046 Iraq. *medRxiv* 2020.06.24.20121905 (2020). doi:10.1101/2020.06.24.20121905
- 1047 24. Gharbharan, A. *et al.* Convalescent Plasma for COVID-19. A randomized clinical trial.
1048 *medRxiv* 2020.07.01.20139857 (2020). doi:10.1101/2020.07.01.20139857
- 1049 25. Martinez-Resendez, M. F. *et al.* Initial experience in Mexico with convalescent plasma in
1050 COVID-19 patients with severe respiratory failure, a retrospective case series. *medRxiv*
1051 2020.07.14.20144469 (2020). doi:10.1101/2020.07.14.20144469
- 1052 26. Zhang, B. *et al.* Treatment With Convalescent Plasma for Critically Ill Patients With
1053 Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Chest* **158**, e9–e13 (2020).
- 1054 27. Ahn, J. Y. *et al.* Use of Convalescent Plasma Therapy in Two COVID-19 Patients with
1055 Acute Respiratory Distress Syndrome in Korea. *J. Korean Med. Sci.* **35**, (2020).
- 1056 28. Pei, S. *et al.* Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences.
1057 *medRxiv* (2020). doi:10.1101/2020.04.07.20056440
- 1058 29. Ye, M. *et al.* Treatment with convalescent plasma for COVID-19 patients in Wuhan,
1059 China. *J. Med. Virol.* 1–12 (2020). doi:10.1002/jmv.25882

- 1060 30. Zeng, Q.-L. *et al.* Effect of Convalescent Plasma Therapy on Viral Shedding and Survival
1061 in Patients With Coronavirus Disease 2019. *J. Infect. Dis.* **222**, 38–43 (2020).
- 1062 31. Salazar, E. *et al.* Treatment of Coronavirus Disease 2019 (COVID-19) Patients with
1063 Convalescent Plasma. *Am. J. Pathol.* **190**, 1680–1690 (2020).
- 1064 32. H Liu, S. T. *et al.* Convalescent plasma treatment of severe COVID-19: A matched
1065 control study. *medRxiv* (2020). doi:10.1101/2020.05.20.20102236
- 1066 33. Perotti, C. *et al.* Mortality reduction in 46 severe Covid-19 patients treated with
1067 hyperimmune plasma. A proof of concept single arm multicenter interventional trial co-
1068 first authors with equal contribution. *medRxiv* (2020). doi:10.1101/2020.05.26.20113373
- 1069 34. Ni, L. *et al.* Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in
1070 COVID-19 Convalescent Individuals. *Immunity* **52**, 971–977 (2020).
- 1071 35. Stadlbauer, D. *et al.* Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2
1072 seroprevalence in New York City. *medRxiv* (2020). doi:10.1101/2020.06.28.20142190
- 1073 36. Bosch, B. J., van der Zee, R., de Haan, C. A. M. & Rottier, P. J. M. The Coronavirus
1074 Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization
1075 of the Fusion Core Complex. *J. Virol.* **77**, 8801–8811 (2003).
- 1076 37. Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu. Rev. Virol.*
1077 **3**, 237–261 (2016).
- 1078 38. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
1079 conformation. *Science (80-.)*. **367**, 1260–1263 (2020).
- 1080 39. Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor
1081 usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat. Microbiol.* **5**, 562–
1082 569 (2020).

- 1083 40. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
1084 Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8 (2020).
- 1085 41. Hamming, I. *et al.* Tissue distribution of ACE2 protein, the functional receptor for SARS
1086 coronavirus. A first step in understanding SARS pathogenesis. *J. Pathol.* **203**, 631–637
1087 (2004).
- 1088 42. Glowacka, I. *et al.* Evidence that TMPRSS2 Activates the Severe Acute Respiratory
1089 Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by
1090 the Humoral Immune Response. *J. Virol.* **85**, 4122–4134 (2011).
- 1091 43. Menachery, V. D. *et al.* Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus
1092 Infection. *J. Virol.* **94**, (2019).
- 1093 44. Shang, J. *et al.* Cell entry mechanisms of SARS-CoV-2. *Proc. Natl. Acad. Sci.* **117**,
1094 11727–11734 (2020).
- 1095 45. Matsuyama, S. *et al.* Efficient Activation of the Severe Acute Respiratory Syndrome
1096 Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2. *J. Virol.* **84**,
1097 12658–12664 (2010).
- 1098 46. Shulla, A. *et al.* A Transmembrane Serine Protease Is Linked to the Severe Acute
1099 Respiratory Syndrome Coronavirus Receptor and Activates Virus Entry. *J. Virol.* **85**, 873–
1100 882 (2011).
- 1101 47. Mousavizadeh, L. & Ghasemi, S. Genotype and phenotype of COVID-19: Their roles in
1102 pathogenesis. *J. Microbiol. Immunol. Infect.* (2020). doi:10.1016/j.jmii.2020.03.022
- 1103 48. Gallagher, T. M. & Buchmeier, M. J. Coronavirus Spike Proteins in Viral Entry and
1104 Pathogenesis. *Virology* **279**, 371–374 (2001).
- 1105 49. Simmons, G., Zmora, P., Gierer, S., Heurich, A. & Pöhlmann, S. Proteolytic activation of

- 1106 the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral
1107 research. *Antiviral Res.* **100**, 605–614 (2013).
- 1108 50. Tang, T., Bidon, M., Jaimes, J. A., Whittaker, G. R. & Daniel, S. Coronavirus membrane
1109 fusion mechanism offers a potential target for antiviral development. *Antiviral Res.* **178**,
1110 104792 (2020).
- 1111 51. Matsuyama, S. *et al.* Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.
1112 *Proc. Natl. Acad. Sci.* **117**, 7001–7003 (2020).
- 1113 52. Hofmann, H. *et al.* S Protein of Severe Acute Respiratory Syndrome-Associated
1114 Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing
1115 Antibodies in Infected Patients. *J. Virol.* **78**, 6134–6142 (2004).
- 1116 53. Simmons, G. *et al.* Characterization of severe acute respiratory syndrome-associated
1117 coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. *Proc. Natl. Acad. Sci.*
1118 *U. S. A.* **101**, 4240–4245 (2004).
- 1119 54. Yang, Z.-Y. *et al.* pH-Dependent Entry of Severe Acute Respiratory Syndrome
1120 Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell
1121 Transfer through DC-SIGN. *J. Virol.* **78**, 5642–5650 (2004).
- 1122 55. Zheng, M. & Song, L. Novel antibody epitopes dominate the antigenicity of spike
1123 glycoprotein in SARS-CoV-2 compared to SARS-CoV. *Cell. Mol. Immunol.* **17**, 536–538
1124 (2020).
- 1125 56. Okba, N. M. A. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2–Specific
1126 Antibody Responses in Coronavirus Disease Patients. *Emerg. Infect. Dis.* **26**, 1478–1488
1127 (2020).
- 1128 57. Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus

- 1129 disease 2019. *Clin. Infect. Dis.* (2020). doi:10.1093/cid/ciaa344
- 1130 58. Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019.
1131 *Nature* **581**, 465–469 (2020).
- 1132 59. To, K. K. W. *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva
1133 samples and serum antibody responses during infection by SARS-CoV-2: an observational
1134 cohort study. *Lancet Infect. Dis.* **20**, 565–574 (2020).
- 1135 60. Wu, L.-P. *et al.* Duration of Antibody Responses after Severe Acute Respiratory
1136 Syndrome. *Emerg. Infect. Dis.* **13**, 1562–1564 (2007).
- 1137 61. Xiao, A. T., Tong, Y. X. & Zhang, S. False negative of RT-PCR and prolonged nucleic
1138 acid conversion in COVID-19: Rather than recurrence. *J. Med. Virol.* **30329**, jmv.25855
1139 (2020).
- 1140 62. Xing, Y. *et al.* Post-discharge surveillance and positive virus detection in two medical
1141 staff recovered from coronavirus disease 2019 (COVID-19), China, January to February
1142 2020. *Eurosurveillance* **25**, 2–5 (2020).
- 1143 63. Bao, L. *et al.* Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2.
1144 *bioRxiv* (2020). doi:10.1101/2020.03.13.990226
- 1145 64. Chandrashekar, A. *et al.* SARS-CoV-2 infection protects against rechallenge in rhesus
1146 macaques. *Science* (80-.). (2020). doi:10.1126/science.abc4776
- 1147 65. Holmes, K. V. SARS coronavirus □: a new challenge for prevention and therapy. *J. Clin.*
1148 *Invest.* **111**, 1605–1609 (2003).
- 1149 66. Cavanagh, D. Coronaviruses and Toroviruses. in *Principles and Practice of Clinical*
1150 *Virology* 379–397 (John Wiley & Sons, Ltd, 2009). doi:10.1002/0470020970.ch10
- 1151 67. Kellam, P. & Barclay, W. The dynamics of humoral immune responses following SARS-

- 1152 CoV-2 infection and the potential for reinfection. *J. Gen. Virol.* (2020).
1153 doi:10.1099/jgv.0.001439
- 1154 68. Ibarrondo, F. J. *et al.* Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild
1155 Covid-19. *N. Engl. J. Med.* NEJMc2025179 (2020). doi:10.1056/NEJMc2025179
- 1156 69. Wang, K. *et al.* Longitudinal dynamics of the neutralizing antibody response to SARS-
1157 CoV-2 infection. *medRxiv* doi:10.1101/2020.07.14.20151159
- 1158 70. Seow, J. *et al.* Longitudinal evaluation and decline of antibody responses in SARS-CoV-2
1159 infection. *medRxiv* (2020). doi:10.1101/2020.07.09.20148429
- 1160 71. Long, Q.-X. *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2
1161 infections. *Nat. Med.* (2020). doi:10.1038/s41591-020-0965-6
- 1162 72. Liu, W. *et al.* Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked
1163 Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. *J. Clin.*
1164 *Microbiol.* **58**, 1–7 (2020).
- 1165 73. Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans.
1166 *Nat. Med.* **26**, 1033–1036 (2020).
- 1167 74. Caruana, G. *et al.* Diagnostic strategies for SARS-CoV-2 infection and interpretation of
1168 microbiological results. *Clin. Microbiol. Infect.* (2020). doi:10.1016/j.cmi.2020.06.019
- 1169 75. Rogers, T. F. *et al.* Isolation of potent SARS-CoV-2 neutralizing antibodies and protection
1170 from disease in a small animal model. *Science (80-.).* **7520**, eabc7520 (2020).
- 1171 76. Seydoux, E. *et al.* Analysis of a SARS-CoV-2-Infected Individual Reveals Development
1172 of Potent Neutralizing Antibodies with Limited Somatic Mutation. *Immunity* **53**, 98-
1173 105.e5 (2020).
- 1174 77. Wu, Y. *et al.* Identification of Human Single-Domain Antibodies against SARS-CoV-2.

- 1175 *Cell Host Microbe* **27**, 891–898 (2020).
- 1176 78. Wec, A. Z. *et al.* Broad neutralization of SARS-related viruses by human monoclonal
1177 antibodies. *Science (80-.)*. **7424**, (2020).
- 1178 79. Manenti, A. *et al.* Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based
1179 colorimetric live virus micro-neutralization assay in human serum samples. *J. Med. Virol.*
1180 *jmv.25986* (2020). doi:10.1002/jmv.25986
- 1181 80. Perera, R. A. *et al.* Serological assays for severe acute respiratory syndrome coronavirus 2
1182 (SARS-CoV-2), March 2020. *Eurosurveillance* **25**, (2020).
- 1183 81. Bohn, M. K. *et al.* Molecular, serological, and biochemical diagnosis and monitoring of
1184 COVID-19: IFCC taskforce evaluation of the latest evidence. *Clin. Chem. Lab. Med.* **58**,
1185 1037–1052 (2020).
- 1186 82. Özçürümez, M. K. *et al.* SARS-CoV-2 antibody testing—questions to be asked. *J. Allergy*
1187 *Clin. Immunol.* **146**, 35–43 (2020).
- 1188 83. Tan, C. W. *et al.* A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on
1189 antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction. *Res. Sq.*
1190 (2020). doi:10.21203/rs.3.rs-24574/v1
- 1191 84. Liu, L. *et al.* Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2
1192 spike. *Nature* (2020). doi:10.1038/s41586-020-2571-7
- 1193 85. Chi, X. *et al.* A neutralizing human antibody binds to the N-terminal domain of the Spike
1194 protein of SARS-CoV-2. *Science (80-.)*. eabc6952 (2020). doi:10.1126/science.abc6952
- 1195 86. Gorse, G. J., Donovan, M. M. & Patel, G. B. Antibodies to coronaviruses are higher in
1196 older compared with younger adults and binding antibodies are more sensitive than
1197 neutralizing antibodies in identifying coronavirus-associated illnesses. *J. Med. Virol.* **92**,

- 1198 512–517 (2020).
- 1199 87. Takada, A. *et al.* A system for functional analysis of Ebola virus glycoprotein. *Proc. Natl.*
1200 *Acad. Sci.* **94**, 14764–14769 (1997).
- 1201 88. Negrete, O. A. *et al.* EphrinB2 is the entry receptor for Nipah virus, an emergent deadly
1202 paramyxovirus. *Nature* **436**, 401–405 (2005).
- 1203 89. Avanzato, V. A. *et al.* A structural basis for antibody-mediated neutralization of Nipah
1204 virus reveals a site of vulnerability at the fusion glycoprotein apex. *Proc. Natl. Acad. Sci.*
1205 **116**, 25057–25067 (2019).
- 1206 90. Zettl, F. *et al.* Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using
1207 Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. *Vaccines* **8**, 386 (2020).
- 1208 91. Shirato, K., Kawase, M. & Matsuyama, S. Wild-type human coronaviruses prefer cell-
1209 surface TMPRSS2 to endosomal cathepsins for cell entry. *Virology* **517**, 9–15 (2018).
- 1210 92. Wang, C. *et al.* A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat.*
1211 *Commun.* **11**, 1–6 (2020).
- 1212 93. Johnson, M. C. *et al.* Optimized pseudotyping conditions for the SARS-COV2 Spike
1213 glycoprotein 2. *bioRxiv* doi:doi.org/10.1101/2020.05.28.122671
- 1214 94. Aguilar, H. C., Anderson, W. F. & Cannon, P. M. Cytoplasmic tail of Moloney murine
1215 leukemia virus envelope protein influences the conformation of the extracellular domain:
1216 implications for mechanism of action of the R Peptide. *J. Virol.* **77**, 1281–91 (2003).
- 1217 95. Bosch, B. J., de Haan, C. A. M., Smits, S. L. & Rottier, P. J. M. Spike protein assembly
1218 into the coronavirion: exploring the limits of its sequence requirements. *Virology* **334**,
1219 306–318 (2005).
- 1220 96. Shulla, A. & Gallagher, T. Role of Spike Protein Endodomains in Regulating Coronavirus

- 1221 Entry. *J. Biol. Chem.* **284**, 32725–32734 (2009).
- 1222 97. McBride, C. E. & Machamer, C. E. Palmitoylation of SARS-CoV S protein is necessary
1223 for partitioning into detergent-resistant membranes and cell–cell fusion but not interaction
1224 with M protein. *Virology* **405**, 139–148 (2010).
- 1225 98. Lin, H.-X. *et al.* Characterization of the spike protein of human coronavirus NL63 in
1226 receptor binding and pseudotype virus entry. *Virus Res.* **160**, 283–293 (2011).
- 1227 99. Wyss, S. *et al.* Regulation of Human Immunodeficiency Virus Type 1 Envelope
1228 Glycoprotein Fusion by a Membrane-Interactive Domain in the gp41 Cytoplasmic Tail. *J.*
1229 *Virol.* **79**, 12231–12241 (2005).
- 1230 100. Edwards, T. G. *et al.* Truncation of the Cytoplasmic Domain Induces Exposure of
1231 Conserved Regions in the Ectodomain of Human Immunodeficiency Virus Type 1
1232 Envelope Protein. *J. Virol.* **76**, 2683–2691 (2002).
- 1233 101. Waning, D. L., Russell, C. J., Jardetzky, T. S. & Lamb, R. A. Activation of a
1234 paramyxovirus fusion protein is modulated by inside-out signaling from the cytoplasmic
1235 tail. *Proc. Natl. Acad. Sci.* **101**, 9217–9222 (2004).
- 1236 102. da Silva, E., Mulinge, M. & Bercoff, D. The frantic play of the concealed HIV envelope
1237 cytoplasmic tail. *Retrovirology* **10**, 54 (2013).
- 1238 103. Aguilar, H. C. *et al.* Polybasic KKR Motif in the Cytoplasmic Tail of Nipah Virus Fusion
1239 Protein Modulates Membrane Fusion by Inside-Out Signaling. *J. Virol.* **81**, 4520–4532
1240 (2007).
- 1241 104. Negrete, O. A. *et al.* Two Key Residues in EphrinB3 Are Critical for Its Use as an
1242 Alternative Receptor for Nipah Virus. *PLoS Pathog.* **2**, 0078–0086 (2006).
- 1243 105. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is

- 1244 Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e8 (2020).
- 1245 106. Stadlbauer, D. *et al.* SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a
1246 Serological Assay, Antigen Production, and Test Setup. *Curr. Protoc. Microbiol.* **57**,
1247 (2020).
- 1248 107. Heurich, A. *et al.* TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only
1249 Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory
1250 Syndrome Coronavirus Spike Protein. *J. Virol.* **88**, 1293–1307 (2014).
- 1251 108. Afar, D. E. H. *et al.* Catalytic Cleavage of the Androgen-regulated TMPRSS2 Protease
1252 Results in Its Secretion by Prostate and Prostate Cancer Epithelia. *Cancer Res.* **61**, 1686
1253 LP – 1692 (2001).
- 1254 109. Joyner, M. J. *et al.* Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000
1255 Patients. *medRxiv* (2020). doi:10.1101/2020.05.12.20099879
- 1256 110. Muruato, A. E. *et al.* A high-throughput neutralizing antibody assay for COVID-19
1257 diagnosis and vaccine evaluation. *bioRxiv* 2020.05.21.109546 (2020).
1258 doi:10.1101/2020.05.21.109546
- 1259 111. Crawford, K. H. D. *et al.* Protocol and Reagents for Pseudotyping Lentiviral Particles with
1260 SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12**, 513 (2020).
- 1261 112. Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose-Response Analysis Using R. *PLoS*
1262 *One* **10**, e0146021 (2015).
- 1263 113. Sebaugh, J. L. Guidelines for accurate EC50/IC50 estimation. *Pharm. Stat.* **10**, 128–134
1264 (2011).
- 1265 114. Figar, S. *et al.* Community-level SARS-CoV-2 Seroprevalence Survey in urban slum
1266 dwellers of Buenos Aires City, Argentina: a participatory research. *medRxiv* (2020).

1267 doi:10.1101/2020.07.14.20153858

1268

Figure 1. Production of VSV Δ G-rLuc bearing SARS-CoV-2 spike glycoprotein.







Figure 2. CoV2pp entry is enhanced by trypsin treatment.





Figure 3. Trypsin-treated CoV2pp depend on ACE2 and TMPRSS2 for entry.

A.



B.






Figure 4. CoV2pp viral neutralization assay and absIC50/90 versus Spike binding of patient sera.


A.



B.



C.



D.






Figure 5. CoV2pp viral neutralization assay validated against patient sera by external groups.

A.



B.



C.





Table 1. Comparison of ELISA endpoint titers to CoV2pp neutralization.


		IC ₅₀ Summary [fraction of samples (%)]			IC ₈₀ Summary [fraction of samples (%)]		
		≥ 25 th percentile	≥ median	≥ 75 th percentile	≥ 25 th percentile	≥ median	≥ 75 th percentile
Endpoint ELISA	320	7/11 (63.6%)	0/11 (0%)	0/11 (0%)	4/11 (36.4%)	1/11 (9.1%)	0/11 (0%)
	960	6/8 (75%)	4/8 (50%)	0/8 (0%)	7/8 (87.5%)	4/8 (50%)	1/8 (12.5%)
	2880	11/11 (100%)	11/11 (100%)	10/11 (90.9%)	11/11 (100%)	10/11 (90.9%)	5/11 (45.5%)

Figure 6. 293T stably transduced with ACE2 and TMPRSS2 (293T-ACE2+TMPRSS2) are ultra-permissive for SARS-CoV-2pp infection


A.



B.



C.



D.





Figure 7. Ultra-permissive 293T-ACE2+TMPRSS2 cell clones retains the same phenotypic sensitivity to convalescent COVID-19 sera.

A.



B.

